image_name stringlengths 68 68 | type stringclasses 2
values | gt_table stringlengths 116 12.6k | table_fragment_1 stringlengths 43 8.42k | table_fragment_2 stringlengths 39 8.21k |
|---|---|---|---|---|
4bbe442954ab7528ec14558ce4cce88c936bf64d593478e140df4af314982427.png | simple | <table><tr><td>Amino Acid</td><td>mg/g Crude Protein</td><td>FAO Report mg/g Protein <sup>a</sup></td><td>AAS</td></tr><tr><td>histidine</td><td>38.6 ± 2.3</td><td>16</td><td>2.41</td></tr><tr><td>isoleucine</td><td>54.5 ± 0.0</td><td>30</td><td>1.82</td></tr><tr><td>leucine</td><td>102.1 ± 0.1</td><td>6... | <table><tr><td>Amino Acid</td><td>mg/g Crude Protein</td></tr><tr><td>histidine</td><td>38.6 ± 2.3</td></tr><tr><td>isoleucine</td><td>54.5 ± 0.0</td></tr><tr><td>leucine</td><td>102.1 ± 0.1</td></tr><tr><td>lysine</td><td>80.2 ± 5.2</td></tr><tr><td>threonine</td><td>44.3 ± 3.2</td></tr><tr><td>tryptophan</td><td>6.0 ... | <table><tr><td>FAO Report mg/g Protein a</td><td>AAS</td></tr><tr><td>16</td><td>2.41</td></tr><tr><td>30</td><td>1.82</td></tr><tr><td>61</td><td>1.67</td></tr><tr><td>48</td><td>1.67</td></tr><tr><td>25</td><td>1.77</td></tr><tr><td>6.6</td><td>0.91</td></tr><tr><td>40</td><td>1.56</td></tr><tr><td>-</td><td>-</td></... |
d39466004cbf68fad9f51f7f9c56163f0ba8fdbcd6ba9ae578e74c97d1366fd9.png | simple | <table><tr><td>Name</td><td>Company</td><td>Catalog number</td><td>Antibody concentration</td></tr><tr><td>DAB2IP</td><td>Abcam</td><td>ab87811</td><td>1 : 1000 or 1 : 200</td></tr><tr><td>E-cadherin</td><td>Cell Signaling Technology</td><td>3195</td><td>1 : 500</td></tr><tr><td>Vimentin</td><td>Cell Signaling Technolo... | <table><tr><td>Name</td></tr><tr><td>DAB2IP</td></tr><tr><td>E-cadherin</td></tr><tr><td>Vimentin</td></tr><tr><td>p-ERK1/2</td></tr><tr><td>ERK1/2</td></tr><tr><td>GAPDH</td></tr><tr><td>α-tubulin</td></tr></table> | <table><tr><td>Company</td><td>Catalog number</td><td>Antibody concentration</td></tr><tr><td>Abcam</td><td>ab87811</td><td>1 : 1000 or 1 : 200</td></tr><tr><td>Cell Signaling Technology</td><td>3195</td><td>1 : 500</td></tr><tr><td>Cell Signaling Technology</td><td>5741</td><td>1 : 500</td></tr><tr><td>Cell Signaling ... |
2d9f6a615a3891c84134293f3cd9bd08be23abf8cd2fb1d13926374221b22c8d.png | complex | <table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (<i>n</i>)</td><td colspan="6">Female (<i>n</i>)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td><i>p</i></td></tr><tr><td>After the delivery, I would not try to establish breastfeeding.... | <table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (n)</td><td colspan="6">Female (n)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>p</td></tr><tr><td>After the delivery, I would not try to establish breastfeeding. I would bottle-feed ... | <table><tr><td rowspan="2">Intentions *</td><td colspan="5">Male (n)</td><td colspan="6">Female (n)</td></tr><tr><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>5</td><td>4</td><td>3</td><td>2</td><td>1</td><td>p</td></tr><tr><td>I would breastfeed my child in accordance with doctors’ recommendations, regardless ... |
8c23bcdced3b9cd33018063ec840857cd2c629205b4a9ae5f3fe41856c29b144.png | simple | <table><tr><td></td><td>Estimate</td><td>Standard Error</td><td>Chi-Square (df = 1) or t-value</td><td>Odds Ratio</td><td>95% Confidence Interval</td><td>p-value</td></tr><tr><td>W1 drinking predicting stroke</td><td>-0.31</td><td>0.10</td><td>10.8</td><td>0.73</td><td>0.61–0.88</td><td>0.001</td></tr><tr><td>W1 ... | <table><tr><td></td><td>Estimate</td><td>Standard Error</td><td>Chi-Square (df = 1) or t-value</td><td>Odds Ratio</td><td>95% Confidence Interval</td><td>p-value</td></tr><tr><td>W1 drinking predicting stroke</td><td>-0.31</td><td>0.10</td><td>10.8</td><td>0.73</td><td>0.61–0.88</td><td>0.001</td></tr><tr><td>W1 drinki... | <table><tr><td>W1 drinking predicting diabetes</td><td>-0.30</td><td>0.13</td><td>5.4</td><td>0.74</td><td>0.57–0.95</td><td>0.02</td></tr><tr><td>W1 drinking predicting falls</td><td>-0.09</td><td>0.06</td><td>2.5</td><td>0.91</td><td>0.81–1.02</td><td>0.12</td></tr><tr><td>W1 drinking predicting hip fracture</td><td>... |
1460ce6985beef2d512ce7a02207eab4ea5d969effb6920e73cc4d09e91b2a85.png | complex | <table><tr><td colspan="4">WNV-L vs. E</td><td colspan="4">CHIKV-L vs. E</td></tr><tr><td>Symbol</td><td>Entrez gene name</td><td>Log<sub>2</sub> fold change</td><td><i>P</i>-value</td><td>Symbol</td><td>Entrez gene name</td><td>Log<sub>2</sub> fold change</td><td><i>P</i>-value</td></tr><tr><td>Lcn2</td><td>Lipocalin ... | <table><tr><td colspan="4">WNV-L vs. E</td><td colspan="2">CHIKV-L vs. E</td></tr><tr><td>Symbol</td><td>Entrez gene name</td><td>Log2 fold change</td><td>P-value</td><td>Symbol</td><td>Entrez gene name</td></tr><tr><td>Lcn2</td><td>Lipocalin 2</td><td>4.87</td><td>6.81E-10</td><td>Cxcl10</td><td>Chemokine (C-X-C motif... | <table><tr><td colspan="2">CHIKV-L vs. E</td></tr><tr><td>Log2 fold change</td><td>P-value</td></tr><tr><td>5.09</td><td>4.38E-13</td></tr><tr><td>4.73</td><td>4.48E-09</td></tr><tr><td>4.19</td><td>4.22E-10</td></tr><tr><td>4.18</td><td>5.19E-11</td></tr><tr><td>4.13</td><td>1.34E-13</td></tr><tr><td>4.12</td><td>5.84... |
e8931ba2069a2e9c61ffe2a5bd335d08a0e50c4792904dec98cd8bdf41133020.png | complex | <table><tr><td></td><td colspan="10"><i>Pol</i> subtype</td></tr><tr><td><i>Env</i> subtype</td><td>A</td><td>B</td><td>C</td><td>D</td><td>F</td><td>G</td><td>H</td><td>01_AE</td><td>02_AG</td><td>UA</td></tr><tr><td>A-like</td><td>59</td><td></td><td></td><td>3</td><td>1</td><td>3</td><td></td><td>1</td><td>71</td><t... | <table><tr><td></td><td colspan="10">Pol subtype</td></tr><tr><td>Env subtype</td><td>A</td><td>B</td><td>C</td><td>D</td><td>F</td><td>G</td><td>H</td><td>01_AE</td><td>02_AG</td><td>UA</td></tr></table> | <table><tr><td>A-like</td><td>59</td><td></td><td></td><td>3</td><td>1</td><td>3</td><td></td><td>1</td><td>71</td><td>16</td></tr><tr><td>B</td><td>3</td><td>1</td><td></td><td></td><td></td><td>4</td><td></td><td></td><td>2</td><td>2</td></tr><tr><td>C</td><td>1</td><td></td><td>62</td><td></td><td></td><td></td><td>... |
5535753c8bc884bdd0efc400bc2badc105fd444c3f2d715fb6b6f69af12b8ef2.png | simple | <table><tr><td></td><td>Range</td><td>Mean (SD)</td></tr><tr><td>Temperature, centigrade</td><td>36–38</td><td>37 ± 0.5</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>100–190</td><td>140 ± 24</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>60–140</td><td>86 ± 22</td></tr... | <table><tr><td></td><td>Range</td><td>Mean (SD)</td></tr><tr><td>Temperature, centigrade</td><td>36–38</td><td>37 ± 0.5</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>100–190</td><td>140 ± 24</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>60–140</td><td>86 ± 22</td></tr></table> | <table><tr><td>Heart rate</td><td>66–100</td><td>84 ± 11</td></tr><tr><td>Respiratory rate</td><td>14–26</td><td>18 ± 3</td></tr></table> |
6435b7e0a3f2a0e5ac455ce8459047c8fe760d2696e67b5cfe1d0c6a17e846c8.png | complex | <table><tr><td colspan="3"><i>FRR</i> (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>1</td><td>6.00</td><td>2.00</td></tr><tr><td>2</td><td>0.00</td><td>0.00</td></tr><tr><td>3</td><td>2.00</td><td>0.00</td></tr><tr><td>4</td><td>12.00</td><td>16.00</td></tr><tr><td>5</td><td>16.00</td><td>8.... | <table><tr><td colspan="3">FRR (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>1</td><td>6.00</td><td>2.00</td></tr><tr><td>2</td><td>0.00</td><td>0.00</td></tr><tr><td>3</td><td>2.00</td><td>0.00</td></tr><tr><td>4</td><td>12.00</td><td>16.00</td></tr><tr><td>5</td><td>16.00</td><td>8.00</td>... | <table><tr><td colspan="3">FRR (%)</td></tr><tr><td>User</td><td>EEG</td><td>Multi-Task</td></tr><tr><td>6</td><td>2.00</td><td>6.00</td></tr><tr><td>7</td><td>10.00</td><td>6.00</td></tr><tr><td>8</td><td>14.00</td><td>0.00</td></tr><tr><td>9</td><td>8.00</td><td>6.00</td></tr><tr><td>10</td><td>4.00</td><td>4.00</td>... |
066a25e7107fba79e621716a8dc8d073bb5408bda2874828f40d48de53316ffa.png | complex | <table><tr><td rowspan="3">Variables</td><td colspan="5">HOMA-IR quartiles</td></tr><tr><td>Q1</td><td>Q2</td><td>Q3</td><td>Q4</td><td><i>p</i> for linear</td></tr><tr><td>(<1.13)</td><td>(1.13–1.65)</td><td>(1.65–2.65)</td><td>(>2.65)</td><td>trend</td></tr><tr><td><i>Age (years)</i></td><td>10.3 &#... | <table><tr><td rowspan="3">Variables</td><td>HOMA-IR quartiles</td></tr><tr><td>Q1</td></tr><tr><td>(<1.13)</td></tr><tr><td>Age (years)</td><td>10.3 ± 1.9</td></tr><tr><td>Body composition</td><td></td></tr><tr><td>BMI (kg/m2)</td><td>17.3 ± 2.6</td></tr><tr><td>Body fat (%)</td><td>7.9 ± 6.5</td></tr><tr><td>WC (cm)<... | <table><tr><td colspan="4">HOMA-IR quartiles</td></tr><tr><td>Q2</td><td>Q3</td><td>Q4</td><td>p for linear</td></tr><tr><td>(1.13–1.65)</td><td>(1.65–2.65)</td><td>(>2.65)</td><td>trend</td></tr><tr><td>10.3 ± 1.8</td><td>10.8 ± 1.6</td><td>11.4 ± 1.3</td><td><0.001</td></tr><tr><td></td><td></td><td></td><td></td></t... |
032738550710d1c7a84243d90d6a84f04c43ccc2c68b95dba351ae5071aecbe1.png | simple | <table><tr><td>Breeds</td><td>MAF ± s.d.</td><td>Ho ± s.d.</td><td>He ± s.d.</td><td><i>F</i>± s.d.</td><td>N<sub>e</sub></td></tr><tr><td>Valle del Belice</td><td>0.290 ± 0.003</td><td>0.364 ± 0.126</td><td>0.379 ± 0.155</td><td>0.055 ± 0.150</td><td>369</td></tr><tr><td>Comisan... | <table><tr><td>Breeds</td><td>MAF ± s.d.</td><td>Ho ± s.d.</td><td>He ± s.d.</td><td>F± s.d.</td><td>Ne</td></tr><tr><td>Valle del Belice</td><td>0.290 ± 0.003</td><td>0.364 ± 0.126</td><td>0.379 ± 0.155</td><td>0.055 ± 0.150</td><td>369</td></tr><tr><td>Comisana</td><td>0.294 ± 0.004</td><td>0.382 ± 0.129</td><td>0.38... | <table><tr><td>Pinzirita</td><td>0.301 ± 0.005</td><td>0.388 ± 0.122</td><td>0.390 ± 0.108</td><td>0.016 ± 0.042</td><td>685</td></tr></table> |
a077e393df89a339c5e3ef2229589523e044b9ff4ead8ae04652772b11158847.png | simple | <table><tr><td><i>Peg</i></td><td><i>Coupled Score</i></td><td><i>Abstract Coupling Score</i></td><td><i>Function</i></td></tr><tr><td>fig|243277.1.peg.316</td><td>6</td><td>0.38</td><td>Translation elongation factor Tu</td></tr><tr><td>fig|243277.1.peg.318</td><td>39</td><td>0.65</td><td>Transcription antitermination ... | <table><tr><td>Peg</td><td>Coupled Score</td><td>Abstract Coupling Score</td><td>Function</td></tr><tr><td>fig|243277.1.peg.316</td><td>6</td><td>0.38</td><td>Translation elongation factor Tu</td></tr></table> | <table><tr><td>Peg</td><td>Coupled Score</td><td>Abstract Coupling Score</td><td>Function</td></tr><tr><td>fig|243277.1.peg.318</td><td>39</td><td>0.65</td><td>Transcription antitermination protein NusG</td></tr><tr><td>fig|243277.1.peg.319</td><td>24</td><td>0.61</td><td>LSU ribosomal protein L11p (L12e)</td></tr><tr>... |
905e6b01552394c651df9a617c8a19203fe57d963faeceefac903b06534fcebc.png | simple | <table><tr><td>Component score</td><td>SOFA</td><td>MOD</td></tr><tr><td>Cardiovascular</td><td>56%</td><td>18%</td></tr><tr><td>Respiratory</td><td>43%</td><td>23%</td></tr><tr><td>Coagulation</td><td>6%</td><td>4%</td></tr><tr><td>Renal</td><td>0.5%</td><td>0.5%</td></tr><tr><td>Hepatic</td><td>1%</td><td>0%</td></tr... | <table><tr><td>Component score</td><td>SOFA</td><td>MOD</td></tr><tr><td>Cardiovascular</td><td>56%</td><td>18%</td></tr><tr><td>Respiratory</td><td>43%</td><td>23%</td></tr><tr><td>Coagulation</td><td>6%</td><td>4%</td></tr><tr><td>Renal</td><td>0.5%</td><td>0.5%</td></tr></table> | <table><tr><td>Hepatic</td><td>1%</td><td>0%</td></tr></table> |
f4739a4ef2cc53858da1b212d2de0d0dbf07789092d873e05011f35bea5509cf.png | complex | <table><tr><td rowspan="2">Specimens ID</td><td colspan="4">Multiplex</td><td colspan="4">WHO</td></tr><tr><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td></tr><tr><td>20130405-5</td><td>24.26 ± 0.35<sup>a</sup></td><td>24.45 ± 0.21</td><td>25.03 ± 0.3</td><t... | <table><tr><td rowspan="2">Specimens ID</td><td>Multiplex</td></tr><tr><td>Flu A</td></tr><tr><td>20130405-5</td><td>24.26 ± 0.35a</td></tr><tr><td>20130406-32</td><td>26.43 ± 0.21</td></tr><tr><td>20130407-69</td><td>20.15 ± 0.3</td></tr><tr><td>20130409-92</td><td>31.33 ± 0.26</td></tr></table> | <table><tr><td colspan="3">Multiplex</td><td colspan="4">WHO</td></tr><tr><td>H7</td><td>N9</td><td>RP</td><td>Flu A</td><td>H7</td><td>N9</td><td>RP</td></tr><tr><td>24.45 ± 0.21</td><td>25.03 ± 0.3</td><td>20.83 ± 0.3</td><td>24.77 ± 0.31</td><td>25.07 ± 0.15</td><td>24.85 ± 0.5</td><td>21.03 ± 0.3</td></tr><tr><td>2... |
297a37acc88ca8ca520e5de801e031f1817a5409fb2a7333880efadc59113587.png | complex | <table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n ... | <table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n ... | <table><tr><td></td><td colspan="2">Full study population</td><td colspan="5">Nested case-control samples for different case-control ratios</td></tr><tr><td></td><td>DVT +</td><td>DVT-</td><td>Cases</td><td colspan="4">Controls</td></tr><tr><td>Test results</td><td>n = 289</td><td>n = 1006</td><td>n = 289</td><td>1:1n ... |
6509683cc84c1b92dd9f729bb2b6a876d41698311d0781521b7fe0e333c830e5.png | complex | <table><tr><td><i>Plan</i></td><td><i>Plane</i></td><td><i>6 MV Gamma Passing Rate (%)</i></td><td><i>Plane</i></td><td><i>18 MV Gamma Passing Rate (%)</i></td></tr><tr><td>I1 Multitarget</td><td>Isocenter</td><td>93.9</td><td>Isocenter</td><td>95.9</td></tr><tr><td>I2 Mock Prostate</td><td>Isocenter</td><td>91.7</td><... | <table><tr><td>Plan</td><td>Plane</td><td>6 MV Gamma Passing Rate (%)</td><td>Plane</td><td>18 MV Gamma Passing Rate (%)</td></tr><tr><td>I1 Multitarget</td><td>Isocenter</td><td>93.9</td><td>Isocenter</td><td>95.9</td></tr><tr><td>I2 Mock Prostate</td><td>Isocenter</td><td>91.7</td><td>Isocenter</td><td>91.9</td></tr>... | <table><tr><td>Plane</td><td>6 MV Gamma Passing Rate (%)</td><td>Plane</td><td>18 MV Gamma Passing Rate (%)</td></tr><tr><td colspan="2">Overall Standard Deviation</td><td colspan="2">2.3</td></tr><tr><td colspan="2">Overall Confidence Limit</td><td colspan="2">11.0</td></tr></table> |
4ae25d2a65dc77f41d628dbfa418a0a56761a22c0ae3a20cb0c5922d767e74a3.png | complex | <table><tr><td>Transcription factor family</td><td colspan="2">L1 vs. L2 (transcript) Up-or down-regulated</td><td colspan="2">L1 vs. L3 (transcript) Up-or down-regulated</td><td colspan="2">L2 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td></td><td>Up</td><td>Down</td><td>Up</td><td>Down</td><td>Up</td><td>... | <table><tr><td>Transcription factor family</td><td colspan="2">L1 vs. L2 (transcript) Up-or down-regulated</td><td>L1 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td></td><td>Up</td><td>Down</td><td>Up</td></tr><tr><td>AP2</td><td>1</td><td>13</td><td>14</td></tr><tr><td>ARF</td><td>12</td><td>11</td><td>15</... | <table><tr><td>L1 vs. L3 (transcript) Up-or down-regulated</td><td colspan="2">L2 vs. L3 (transcript) Up-or down-regulated</td></tr><tr><td>Down</td><td>Up</td><td>Down</td></tr><tr><td>0</td><td>4</td><td>10</td></tr><tr><td>10</td><td>17</td><td>8</td></tr><tr><td></td><td></td><td></td></tr><tr><td>15</td><td>8</td>... |
101cdfdc69501b7e1b6f6787c807b5a7c325f14fa11db990f1a7a04702214b50.png | complex | <table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Heartburn</td><td>2.05</td><td>0.85</td><td>1.52</td><td>0.74</td></tr><tr><td>Regurgitation</td><td>1.36</... | <table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Heartburn</td><td>2.05</td><td>0.85</td><td>1.52</td><td>0.74</td></tr></table> | <table><tr><td>RDQ Scale</td><td colspan="2">Effect size</td><td colspan="2">Standardized response mean</td></tr><tr><td></td><td>Esomeprazole</td><td>Placebo</td><td>Esomeprazole</td><td>Placebo</td></tr><tr><td>Regurgitation</td><td>1.36</td><td>0.63</td><td>1.31</td><td>0.60</td></tr><tr><td>Dyspepsia</td><td>1.05</... |
162d54cd39327270a11d6cb62707a919cfb212e6072f6cf309b9a330859f37d5.png | complex | <table><tr><td></td><td colspan="3">Median $ (IQR)</td></tr><tr><td></td><td>MostPopular1</td><td>First-linequality-assured ACT</td><td>Oral Artemisinin Monotherapy</td></tr><tr><td>Benin<sup>2</sup></td><td>0.65 <sup>a </sup>(0.43, 1.08) N = 462</td><td>3.24 <sup>b </sup>(1.94, 5.77) N = 216</td><td>8.10 (8.07, 10.45)... | <table><tr><td></td><td>Median $ (IQR)</td></tr><tr><td></td><td>MostPopular1</td></tr><tr><td>Benin2</td><td>0.65 a (0.43, 1.08) N = 462</td></tr><tr><td>DRC</td><td>0.39 a (0.26, 0.52) N = 1, 258</td></tr><tr><td>Madagascar</td><td>0.36 a (0.36, 0.36) N = 1, 847</td></tr><tr><td>Nigeria3</td><td>0.54 a (0.40, 0.81) N... | <table><tr><td colspan="2">Median $ (IQR)</td></tr><tr><td>First-linequality-assured ACT</td><td>Oral Artemisinin Monotherapy</td></tr><tr><td>3.24 b (1.94, 5.77) N = 216</td><td>8.10 (8.07, 10.45) N = 56</td></tr><tr><td>1.86 b (1.03, 3.61) N = 252</td><td>3.23 (2.45, 4.13) N = 956</td></tr><tr><td>0.14 b (0.10, 0.57)... |
7dd7c8a9a8daf28191c26ea351d402572713e3081378160d0afc4d6dbd16cbac.png | complex | <table><tr><td>Subtypes of epilepsy</td><td>T. gondiin (%)</td><td>Pvalue</td><td>Toxocaran (%)</td><td>Pvalue</td></tr><tr><td>Idiopathic</td><td>16/117 (13.67)</td><td rowspan="3">0.8</td><td>25/117(21.36)</td><td rowspan="3">0.2</td></tr><tr><td>Febrile seizure(Special syndrome)</td><td>2/10 (20)</td><td>0/10(0)</td... | <table><tr><td>Subtypes of epilepsy</td></tr><tr><td>Idiopathic</td></tr><tr><td>Febrile seizure(Special syndrome)</td></tr><tr><td>Generalized</td></tr></table> | <table><tr><td>T. gondiin (%)</td><td>Pvalue</td><td>Toxocaran (%)</td><td>Pvalue</td></tr><tr><td>16/117 (13.67)</td><td rowspan="3">0.8</td><td>25/117(21.36)</td><td rowspan="3">0.2</td></tr><tr><td>2/10 (20)</td><td>0/10(0)</td></tr><tr><td>2/14 (14.28)</td><td>3/14 (21.42)</td></tr></table> |
910c31ed505cf4e16b15020417cd62a7e975c5b42d96660564fad4b3fd0fcd83.png | simple | <table><tr><td>Anamnestic and clinicalFeatures of red flags</td><td>Sign and symptoms ofSpecific shoulder pain</td></tr><tr><td>Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainti... | <table><tr><td>Anamnestic and clinicalFeatures of red flags</td><td>Sign and symptoms ofSpecific shoulder pain</td></tr></table> | <table><tr><td>Fever, shivering, changes in body temperature overnight, diaphoresis, nausea, unexplainable sweating overnight, vomiting, sphincteric complaints, diarrhoea, paleness, fatigue, lurching, fainting, exhaustion, excessive and unexplainable weakness, not linked to any physical effort, unexplainable loss of we... |
8e11f27ded25eb4e1e5470e2262445211cc049fdc8c5026ccdf655c7aadc0f11.png | simple | <table><tr><td>Measure(n=)</td><td>HIF-1αH-scoreMean(± sd)</td><td>GLUT-1H-scoreMean(± sd)</td><td>CA-IXH-scoreMean(± sd)</td><td>MVDfrequencyhigh(%)</td><td>CK 5/6frequencypositive(%)</td><td>VEGF-Apg/mlMean(± sd)</td><td>IGF-1ng/mlMean(± sd)</td></tr><tr><td>Nodal status<sup>1</sup></td>... | <table><tr><td>Measure(n=)</td><td>HIF-1αH-scoreMean(± sd)</td><td>GLUT-1H-scoreMean(± sd)</td><td>CA-IXH-scoreMean(± sd)</td><td>MVDfrequencyhigh(%)</td><td>CK 5/6frequencypositive(%)</td><td>VEGF-Apg/mlMean(± sd)</td><td>IGF-1ng/mlMean(± sd)</td></tr><tr><td>Nodal status1</td><td>0.073</td><td>0.22</td><td>0.0068</td... | <table><tr><td>Positive (22)</td><td>62.61(± 46.72)</td><td>107.16(± 38.92)</td><td>44.54(± 24.22)</td><td>5/22(22.73%)</td><td>2/22(9.09%)</td><td>364.36(± 176.92)</td><td>113.85(± 29.64)</td></tr></table> |
80e89249b75fa7745b3b92fd472f41e4dbb724d387c781189364459c8128479a.png | simple | <table><tr><td></td><td>ρ</td><td>ρ-partial</td></tr><tr><td>Baseline disability</td><td>0.46<sup>‡</sup></td><td></td></tr><tr><td>Age</td><td>0.26<sup>‡</sup></td><td>0.28<sup>‡</sup></td></tr><tr><td>Somatization</td><td>0.40<sup>‡</sup></td><td>0.23<sup>‡</sup></td></tr><tr><... | <table><tr><td></td></tr><tr><td>Baseline disability</td></tr><tr><td>Age</td></tr><tr><td>Somatization</td></tr><tr><td>Depression</td></tr><tr><td>Time since onset of pain</td></tr><tr><td>Coping resources</td></tr><tr><td>Resilience</td></tr><tr><td>Gender</td></tr></table> | <table><tr><td>ρ</td><td>ρ-partial</td></tr><tr><td>0.46‡</td><td></td></tr><tr><td>0.26‡</td><td>0.28‡</td></tr><tr><td>0.40‡</td><td>0.23‡</td></tr><tr><td>0.35‡</td><td>0.25‡</td></tr><tr><td>0.14†</td><td>0.13†</td></tr><tr><td>−0.15†</td><td>−0.12*</td></tr><tr><td>−0.21‡</td><td>−0.18‡</td></tr><tr><td>0.02</td><... |
67d9a122fa2b71c585df3d4900d1f0200a91d695f0234379bc11c688900c40cd.png | simple | <table><tr><td> </td><td><i>Primary Rd until progression (</i>n<i>=9)</i></td><td><i>Primary Rd stopped before progression (</i>n<i>=11)</i></td><td><i>Primary Rd stopped with progression and restarted (</i>n<i>=5)</i></td><td><i>Rd induction followed by SCT (</i>n<i>=8)</i></td></tr><tr><td>Age, years, median (range)<... | <table><tr><td></td><td>Primary Rd until progression (n=9)</td><td>Primary Rd stopped before progression (n=11)</td><td>Primary Rd stopped with progression and restarted (n=5)</td><td>Rd induction followed by SCT (n=8)</td></tr></table> | <table><tr><td>Age, years, median (range)</td><td>65 (36–70)</td><td>60 (40–78)</td><td>55 (32–75)</td><td>62 (36–73)</td></tr><tr><td>Prior plasma cell disorder, N</td><td>6 (3 MGUS/SMM; 3 plasmacytoma)</td><td>3 (3 MGUS/SMM)</td><td>3 (2 MGUS/SMM; 1 plasmacytoma)</td><td>3 (1 MGUS/SMM; 2 plasmacytoma)</td></tr><tr><t... |
328bbed101b682a059de40ac5cc97baa2cf58280c8e4308eb764cca974fd666f.png | complex | <table><tr><td rowspan="2">Variable</td><td rowspan="2">Control M (SD)</td><td rowspan="2">MCI M (SD)</td><td rowspan="2">AD M (SD)</td><td rowspan="2">P<sup>1</sup></td><td>P*</td><td> </td><td>P*</td><td> </td><td>P*</td></tr><tr><td>Control × MCI</td><td> </td><td>Control × AD</td><td> </td><td>MCI × ... | <table><tr><td rowspan="2">Variable</td><td rowspan="2">Control M (SD)</td><td rowspan="2">MCI M (SD)</td><td rowspan="2">AD M (SD)</td><td rowspan="2">P1</td><td>P*</td><td></td><td>P*</td><td></td><td>P*</td></tr><tr><td>Control × MCI</td><td></td><td>Control × AD</td><td></td><td>MCI × AD</td></tr><tr><td>RAVLT – Im... | <table><tr><td>REC</td><td>14.56 (0.54)</td><td>13.04 (0.39)</td><td>10.48 (0.52)</td><td><0.001</td><td>0.067</td><td><0.001</td><td><0.001</td></tr><tr><td>BNT</td><td>52.84 (1.54)</td><td>49.55 (1.1)</td><td>46.44 (1.41)</td><td>0.012</td><td>0.237</td><td>0.009</td><td>0.234</td></tr></table> |
5741eaf6b90237ad17a282b5a48ffa9f80c407e55b04ea2b662ae49cc093314c.png | complex | <table><tr><td>Input</td><td colspan="3">Membership Function</td></tr><tr><td>RSSI Level</td><td>Weak</td><td>Medium</td><td>Strong</td></tr><tr><td>Number of Neighbours</td><td>Low</td><td>Medium</td><td>High</td></tr><tr><td>Distance to each neighbour</td><td>Near</td><td>Medium</td><td>Far</td></tr></table> | <table><tr><td>Input</td><td colspan="3">Membership Function</td></tr><tr><td>RSSI Level</td><td>Weak</td><td>Medium</td><td>Strong</td></tr></table> | <table><tr><td>Number of Neighbours</td><td>Low</td><td>Medium</td><td>High</td></tr><tr><td>Distance to each neighbour</td><td>Near</td><td>Medium</td><td>Far</td></tr></table> |
46544ca7b0f480ccdeadfeeea0f127320e2ac6856f6fb9d7336c5425b79a04dc.png | complex | <table><tr><td>Characteristic (<i>N =</i> 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> Female</td><td>126</td><td>85.1</td></tr><tr><td>Grade level</td><td></td><td></td></tr><tr><td> Freshman</td><td>36</td><td>24.3</td></tr><tr><td> Sophomore</td><td>38</td><td>25.7<... | <table><tr><td>Characteristic (N = 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Female</td><td>126</td><td>85.1</td></tr><tr><td>Grade level</td><td></td><td></td></tr><tr><td>Freshman</td><td>36</td><td>24.3</td></tr><tr><td>Sophomore</td><td>38</td><td>25.7</td></tr><... | <table><tr><td>Characteristic (N = 148)</td><td>Number</td><td>Percent</td></tr><tr><td>Newspaper</td><td>21</td><td>14.2</td></tr><tr><td>Magazine</td><td>2</td><td>1.4</td></tr><tr><td>Others</td><td>10</td><td>6.8</td></tr></table> |
1e7477e8a4e79c12d9ba99db7c4a72a9f9bed84e364e9313026dca88c304a622.png | simple | <table><tr><td>Degrees of freedom</td><td>90%</td><td>95%</td></tr><tr><td>1</td><td>2.71</td><td>3.84</td></tr><tr><td>2</td><td>4.61</td><td>5.99</td></tr><tr><td>3</td><td>6.25</td><td>7.81</td></tr><tr><td>4</td><td>7.78</td><td>9.49</td></tr></table> | <table><tr><td>Degrees of freedom</td><td>90%</td><td>95%</td></tr><tr><td>1</td><td>2.71</td><td>3.84</td></tr><tr><td>2</td><td>4.61</td><td>5.99</td></tr><tr><td>3</td><td>6.25</td><td>7.81</td></tr></table> | <table><tr><td>4</td><td>7.78</td><td>9.49</td></tr></table> |
6b4d1cc752db497e4d985150024f5ad989fe8813f6e52ce0029d9dee5789efd1.png | simple | <table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td>SCL-90-R</td><td>Without psychopathology > 0.99</td><td>62</td><td>44.6</td></tr><tr><td></td><td>Somatization (SOM) > 0.99</td><td>47</td><td>33.8</td></tr><tr><td></td><td>Obsessive-compulsive (OC) > 0.99</td><td>43</td><td>30.9</td></t... | <table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td>SCL-90-R</td><td>Without psychopathology > 0.99</td><td>62</td><td>44.6</td></tr></table> | <table><tr><td>Scale</td><td>Factor</td><td>N</td><td>%</td></tr><tr><td></td><td>Somatization (SOM) > 0.99</td><td>47</td><td>33.8</td></tr><tr><td></td><td>Obsessive-compulsive (OC) > 0.99</td><td>43</td><td>30.9</td></tr><tr><td></td><td>Interpersonal sensitivity (IS) > 0.99</td><td>19</td><td>13.7</td></tr><tr><td>... |
3bccc8d9e82a743d16f3315e3d83c73139338e208bb11708765d524bbaa8fb05.png | simple | <table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>Balistid fish</td><td>16%</td><td>24%</td><td>11%</td></tr><tr><td>Scarine fish</td><td>83%</td><td>63%</td><td>50%</td></tr><tr><td>Hemiphractid frogs</td><td>64%</td><td>52%</td><td>30%</td>... | <table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>Balistid fish</td><td>16%</td><td>24%</td><td>11%</td></tr><tr><td>Scarine fish</td><td>83%</td><td>63%</td><td>50%</td></tr><tr><td>Hemiphractid frogs</td><td>64%</td><td>52%</td><td>30%</td>... | <table><tr><td>Clade</td><td>Combined-data and mtDNA</td><td>Combined-data and nucDNA</td><td>mtDNA and nucDNA</td></tr><tr><td>odents (Sahul)</td><td>55%</td><td>96%</td><td></td></tr></table> |
be7e1c255029bde7cda06ae6e238b0cdd8a1aac11f07e85df06184e09d0a0c13.png | complex | <table><tr><td></td><td>Mean</td><td>Sd</td><td>Median</td><td>Iqr</td><td><i>P</i>-value</td></tr><tr><td colspan="6">Sex</td></tr><tr><td> M</td><td>118.17</td><td>18.37</td><td>117.5</td><td>17</td><td>0.0326*</td></tr><tr><td> F</td><td>112.46</td><td>19.13</td><td>114</td><td>20</td><td></td></tr><tr><td colspan="... | <table><tr><td></td><td>Mean</td><td>Sd</td><td>Median</td><td>Iqr</td><td>P-value</td></tr><tr><td colspan="6">Sex</td></tr><tr><td>M</td><td>118.17</td><td>18.37</td><td>117.5</td><td>17</td><td>0.0326*</td></tr><tr><td>F</td><td>112.46</td><td>19.13</td><td>114</td><td>20</td><td></td></tr><tr><td colspan="6">Univer... | <table><tr><td colspan="6">Education</td></tr><tr><td>Junior (I – II years)</td><td>112.46</td><td>14.31</td><td>114</td><td>17</td><td>0.0253*</td></tr><tr><td>Senior (III year)</td><td>116.18</td><td>26.59</td><td>118</td><td>24</td><td></td></tr></table> |
4bab918b39dd5e367e5cecea23884918eaa587761664b88272ede27fb2d5a2ff.png | simple | <table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>Nucleus accumbens (nAc)</td><td>Nucleus accumbens (nAc)</td><td>Balint and Csillag (2007), Husband and Shimizu (2011)</td></tr><tr><td>Ventral tegmental area (VTA)</td><td>Ventral tegmental area (VTA)</td><td>Bottjer (1993), Reiner et a... | <table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>Nucleus accumbens (nAc)</td><td>Nucleus accumbens (nAc)</td><td>Balint and Csillag (2007), Husband and Shimizu (2011)</td></tr><tr><td>Ventral tegmental area (VTA)</td><td>Ventral tegmental area (VTA)</td><td>Bottjer (1993), Reiner et a... | <table><tr><td>Human region</td><td>Avian region</td><td>Reference</td></tr><tr><td>s</td><td>teral striatum (LSt)</td><td>arten (1969), Reiner et al. (1998)</td></tr><tr><td>Hippocampus (Hp)</td><td>Hippocampus (Hp)</td><td>Erichsen et al. (1991)</td></tr><tr><td>Medial amygdala (MeA)</td><td>Nucleus taeniae of the am... |
49359ce3f5daf4139004cef752c55d7ed8b66ff0372ce9ea67655efea17d0fae.png | complex | <table><tr><td></td><td>2007</td><td colspan="5">2012</td><td></td></tr><tr><td></td><td></td><td colspan="5">Exposed to the intervention</td><td></td></tr><tr><td rowspan="2"></td><td rowspan="2"></td><td>Never</td><td>Once</td><td>Twice or more</td><td rowspan="2">Total</td><td rowspan="2"><i>p*</i></td><td rowspan="... | <table><tr><td></td><td>2007</td></tr><tr><td></td><td></td></tr><tr><td rowspan="2"></td><td rowspan="2"></td></tr><tr></tr><tr><td>Knowledge of HIV prevention methods</td><td>38.8%</td></tr><tr><td>Condom use during the most recent sexual encounter with a sex worker</td><td>35.5%</td></tr><tr><td>Systematic condom us... | <table><tr><td colspan="5">2012</td><td></td></tr><tr><td colspan="5">Exposed to the intervention</td><td></td></tr><tr><td>Never</td><td>Once</td><td>Twice or more</td><td rowspan="2">Total</td><td rowspan="2">p*</td><td rowspan="2">P**</td></tr><tr><td>(n = 210)</td><td>(n = 63)</td><td>(n = 180)</td></tr><tr><td>59.... |
27342fd9e5ce2f17e5f2853df36d74859aa5636e90f7a9fbf3238ece39dfc004.png | simple | <table><tr><td> </td><td>Mortality 2003</td><td>Mortality 2010</td><td>Unadjusted HR</td><td>Adjusted HR *</td><td>Adjusted HR †</td></tr><tr><td> </td><td>N/total (%)</td><td>N/total (%)</td><td>(95% CI)</td><td>(95% CI)</td><td>(95% CI)</td></tr><tr><td>Total</td><td>333/1624 (20.5)</td><td>488/3809 (12.8)</td>... | <table><tr><td></td><td>Mortality 2003</td><td>Mortality 2010</td><td>Unadjusted HR</td><td>Adjusted HR *</td><td>Adjusted HR †</td></tr><tr><td></td><td>N/total (%)</td><td>N/total (%)</td><td>(95% CI)</td><td>(95% CI)</td><td>(95% CI)</td></tr></table> | <table><tr><td>Total</td><td>333/1624 (20.5)</td><td>488/3809 (12.8)</td><td>0.59 (0.51-0.67)</td><td>0.65 (0.56-0.75)</td><td>0.79 (0.65-0.96)</td></tr><tr><td>LVEF ≤40%</td><td>277/1379 (20.1)</td><td>408/3141 (13.0)</td><td>0.61 (0.52-0.71)</td><td>0.67 (0.57-0.78)</td><td>0.85 (0.69-1.05)</td></tr><tr><td>LVEF >40%... |
7922adb89048dcd95cc2b3449f075661df3cb51facc29134c46b3897f0a222fe.png | simple | <table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td><i>P</i> value</td></tr><tr><td>Nowacki et al. (2004) [4]</td><td>Randomized</td><td>78 (40.4)</td><td>1... | <table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td>P value</td></tr><tr><td>Nowacki et al. (2004) [4]</td><td>Randomized</td><td>78 (40.4)</td><td>10/97(10... | <table><tr><td>Study</td><td>Type of study</td><td>No. of patients receiving short-term radiotherapy (%)</td><td>Experimental group^No of DR/No of patients(%)</td><td>Control groupNo of DR/No of patients (%)</td><td>P value</td></tr><tr><td>Total</td><td>–</td><td>294 (72.9)</td><td>28/204(13.7)</td><td>60/205(29.3)</t... |
ebcc7b910d91f414f46b368af72afdc42c422ddb697601f2fba17506e8f94f0d.png | simple | <table><tr><td>Factor</td><td>Coefficient</td><td><i>Z</i></td><td><i>P</i></td></tr><tr><td>Range (native)</td><td>1.122</td><td>3.16</td><td>0.0016*</td></tr><tr><td>Fish (present)</td><td>0.106</td><td>0.25</td><td>0.8000</td></tr><tr><td>Food Quality (low)</td><td>1.128</td><td>3.18</td><td>0.0015*</td></tr><tr><td... | <table><tr><td>Factor</td><td>Coefficient</td></tr><tr><td>Range (native)</td><td>1.122</td></tr><tr><td>Fish (present)</td><td>0.106</td></tr><tr><td>Food Quality (low)</td><td>1.128</td></tr><tr><td>Range*Fish</td><td>0.042</td></tr><tr><td>Range*Food Quality</td><td>−1.178</td></tr><tr><td>Fish*Food Quality</td><td>... | <table><tr><td>Z</td><td>P</td></tr><tr><td>3.16</td><td>0.0016*</td></tr><tr><td>0.25</td><td>0.8000</td></tr><tr><td>3.18</td><td>0.0015*</td></tr><tr><td>0.09</td><td>0.9300</td></tr><tr><td>−2.67</td><td>0.0075*</td></tr><tr><td>−1.88</td><td>0.0600</td></tr><tr><td>1.99</td><td>0.0470*</td></tr></table> |
a69638a84e030ba5621c0bff1ea17c475c167c4173ca9d2c847e634385125a2d.png | complex | <table><tr><td> </td><td colspan="4">Number of parathyroid glands in resected specimen</td><td colspan="2"><i>P</i>-value</td></tr><tr><td>Variable</td><td>0 (A) N = 364</td><td>1(B) N = 80</td><td>2 or more (C) N = 10</td><td>Total n = 454</td><td>A versus B</td><td>B versus C</td></tr><tr><td>CND</td><td> </td><td> <... | <table><tr><td></td><td colspan="4">Number of parathyroid glands in resected specimen</td><td colspan="2">P-value</td></tr><tr><td>Variable</td><td>0 (A) N = 364</td><td>1(B) N = 80</td><td>2 or more (C) N = 10</td><td>Total n = 454</td><td>A versus B</td><td>B versus C</td></tr><tr><td>CND</td><td></td><td></td><td></... | <table><tr><td>Lateral ND</td><td>51/364 (14.0%)</td><td>18/80 (22.5%)</td><td>2/10 (20%)</td><td>71/454 (15.6%)</td><td>0.062</td><td>0.610</td></tr><tr><td>Operation time (minutes)</td><td>162.2 ± 73.7</td><td>179.1 ± 93.6</td><td>198.0 ± 142.5</td><td>166.0 ± 79.6</td><td>0.218</td><td>0.651</td></tr><tr><td>PTH, pr... |
95af753059c54a6745ead8b12ebca50699dc47f48ded7203dbda49cf4571ca5c.png | complex | <table><tr><td colspan="2">EGFR/ACTB (cutoff 0.05)</td><td colspan="5">EFEMP1/ACTB (cutoff 0.06)</td></tr><tr><td colspan="2">All gliomas<sup>a</sup></td><td colspan="2">All gliomas</td><td>GBM(95 pts, 88 died)</td><td>AA(36 pts, 23 died)</td><td>OT(35 pts, 18 died)</td></tr><tr><td>1.0 (0.7, 1.4)</td><td>P = 0.85</td>... | <table><tr><td colspan="2">EGFR/ACTB (cutoff 0.05)</td><td colspan="5">EFEMP1/ACTB (cutoff 0.06)</td></tr><tr><td colspan="2">All gliomasa</td><td colspan="2">All gliomas</td><td>GBM(95 pts, 88 died)</td><td>AA(36 pts, 23 died)</td><td>OT(35 pts, 18 died)</td></tr></table> | <table><tr><td>1.0 (0.7, 1.4)</td><td>P = 0.85</td><td>0.6 (0.4, 1.0)</td><td>P = 0.037</td><td>0.7 (0.4, 1.1)</td><td>1.0 (0.4, 2.3)</td><td>2.4 (0.5, 11)</td></tr></table> |
25d438393e0b59e8bd5f2c7f1692074c77595703bac48ecbaefb0794a65ae6fc.png | complex | <table><tr><td rowspan="2">Carbon source</td><td rowspan="2">Dry weight of mycelial mat (mg/flask)</td><td rowspan="2">Protein content (mg/ml)</td><td colspan="3">Cellulase</td></tr><tr><td><sup>a</sup>FPase (FPU/ml)</td><td><sup>b</sup>CMCase (U/ml)</td><td><sup>c</sup>Β-glucosidase (U/ml)</td></tr><tr><td>Sarbos... | <table><tr><td rowspan="2">Carbon source</td><td rowspan="2">Dry weight of mycelial mat (mg/flask)</td><td rowspan="2">Protein content (mg/ml)</td><td colspan="3">Cellulase</td></tr><tr><td>aFPase (FPU/ml)</td><td>bCMCase (U/ml)</td><td>cΒ-glucosidase (U/ml)</td></tr></table> | <table><tr><td>Sarbose</td><td>420</td><td>2.17</td><td>3.53</td><td>8.23</td><td>1.16</td></tr><tr><td>Maltose</td><td>369</td><td>2.37</td><td>8.24</td><td>10.35</td><td>1.67</td></tr><tr><td>Sucrose</td><td>275</td><td>2.05</td><td>5.40</td><td>13.18</td><td>1.87</td></tr><tr><td>Lactose</td><td>497</td><td>2.78</td... |
c47fa62011d2415bfcb6e4d33673d2c1c201d1f99ab1f084328938a17e73cb69.png | complex | <table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td rowspan="2">Pronzato <i>et al</i>. [13] 1989</td><td>≤35 days</td><td>116</td><td>Reference</td><td>−</td></tr><tr><td>&... | <table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td>Pronzato et al. [13] 1989</td><td>≤35 days</td><td>116</td><td>Reference</td><td>−</td></tr></table> | <table><tr><td rowspan="2">Source</td><td rowspan="2">WT categories</td><td rowspan="2">Sample size</td><td colspan="2">HR (95%CI)</td></tr><tr><td>OS</td><td>DFS/RFS/EFS</td></tr><tr><td>Pronzato et al. [13] 1989</td><td>>35 days</td><td>113</td><td>2.61 (1.26−5.39)</td><td></td></tr><tr><td rowspan="2">Colleoni et al... |
5bdddfacefc37a5806c147b5d29f408960630240fdde630f069d5b3f47aea7ea.png | complex | <table><tr><td></td><td>Difficulty</td><td>SE</td><td colspan="4">Classified groups for DIF</td><td colspan="2">MNSQ</td></tr><tr><td></td><td>Logits</td><td>Logits</td><td><i>Gender</i></td><td><i>Education</i></td><td><i>Age</i></td><td><i>Disease</i></td><td><i>Outfit</i></td><td><i>Infit</i></td></tr><tr><td colspa... | <table><tr><td></td><td>Difficulty</td><td>SE</td><td colspan="4">Classified groups for DIF</td><td colspan="2">MNSQ</td></tr><tr><td></td><td>Logits</td><td>Logits</td><td>Gender</td><td>Education</td><td>Age</td><td>Disease</td><td>Outfit</td><td>Infit</td></tr><tr><td colspan="9">Interpersonal skills</td></tr><tr><t... | <table><tr><td>6</td><td>0.3</td><td>0.10</td><td>0.06</td><td>0.09</td><td>0.74*</td><td>0.75*</td><td>0.83</td><td>0.80</td></tr><tr><td>7</td><td>0.1</td><td>0.10</td><td>0.04</td><td>0.04</td><td>0.57*</td><td>0.34</td><td>1.05</td><td>1.10</td></tr><tr><td>15</td><td>0.03</td><td>0.10</td><td>0.04</td><td>0.17</td... |
e5142b67824a78e6313e3ca17dbfc1f7ba9f76428ef49c2802a8021bef4bb3c3.png | complex | <table><tr><td rowspan="2">Study groups</td><td colspan="3">No. tested/no. (%) seropositive</td></tr><tr><td>Females</td><td>Males</td><td>Total</td></tr><tr><td>KNP employees with outdoor activity</td><td>5/2 (40)</td><td>23/12 (52.2)</td><td>28/14 (50.0)</td></tr><tr><td>KNP employees with indoor activity</td><td>18/... | <table><tr><td>Study groups</td><td colspan="3">No. tested/no. (%) seropositive</td></tr></table> | <table><tr><td>Study groups</td><td>Females</td><td>Males</td><td>Total</td></tr><tr><td>KNP employees with outdoor activity</td><td>5/2 (40)</td><td>23/12 (52.2)</td><td>28/14 (50.0)</td></tr><tr><td>KNP employees with indoor activity</td><td>18/0 (0.0)</td><td>14/7 (50.0)</td><td>32/7 (21.9)</td></tr><tr><td>Subtotal... |
a578072286f2bfe36de24b657a6b64798886151e8fc016d5d7575c172fb656a5.png | simple | <table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Pure squamous cells carcinoma</td><td>(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.</td></tr><tr><td>Primary head and neck squamous cell carcin... | <table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Pure squamous cells carcinoma</td><td>(i) Entirely composed of squamous cells; (ii) no evidence of another type of thyroid carcinoma in close proximity.</td></tr><tr><td>Primary head and neck squamous cell carcin... | <table><tr><td>Thyroid lesions simulating a squamoid pattern</td><td>Differential features</td></tr><tr><td>Sclerosing mucoepidermoid carcinoma with eosinophilia</td><td>(i) Fibrohyaline stroma;(ii) striking infiltration of eosinophils; (iii) mucin secretion is often present; (iv) typically arising in Hashimoto thyroid... |
724d6cde3059b1e5f72a3c02db0e1311133686ceb4069cf3dc849e186d1a0cc8.png | complex | <table><tr><td rowspan="3"><i>Terms of Delivery</i></td><td colspan="4"><i>Trichomonas vaginalis infection</i></td><td rowspan="3"><i>P-value</i></td></tr><tr><td colspan="2">Study group (positive cases)</td><td colspan="2">Control group (negative cases)</td></tr><tr><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td></tr... | <table><tr><td rowspan="3">Terms of Delivery</td><td colspan="4">Trichomonas vaginalis infection</td><td rowspan="3">P-value</td></tr><tr><td colspan="2">Study group (positive cases)</td><td colspan="2">Control group (negative cases)</td></tr><tr><td>No.</td><td>(%)</td><td>No.</td><td>(%)</td></tr><tr><td>Preterm bi</... | <table><tr><td>rth</td><td>19</td><td>(54.28)</td><td>6</td><td></td><td>1</td></tr><tr><td>Full term birth</td><td>14</td><td>(40)</td><td>216</td><td>(81.5)</td><td>0.001</td></tr><tr><td>Post term birth</td><td>2</td><td>(5.7)</td><td>13</td><td>(4.9)</td><td>0.83</td></tr><tr><td>Total</td><td>35</td><td>(100)</td>... |
6cbba4646d94def7de14c3bce2974585960be875ffa59e61efcd82127fd8ee16.png | complex | <table><tr><td rowspan="2">Assumptions</td><td colspan="4">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Moderate-risk [millions]</td><td>High-risk [millions]</td><td>Population [millions]</td><td>Combined [millions]</td></tr><tr><td colspan="5">Base case assumptions:</td></tr>... | <table><tr><td rowspan="2">Assumptions</td><td colspan="2">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Moderate-risk [millions]</td><td>High-risk [millions]</td></tr><tr><td colspan="3">Base case assumptions:</td></tr><tr><td>Flat background diabetes incidence rate*</td><td r... | <table><tr><td colspan="2">Projected reduction in diabetes prevalence compared to no intervention</td></tr><tr><td>Population [millions]</td><td>Combined [millions]</td></tr><tr><td colspan="2">Base case assumptions:</td></tr><tr><td rowspan="3">0.3 [0.7]</td><td rowspan="3">1.4 [3.6]</td></tr><tr></tr><tr></tr><tr><td... |
4c07617c1a54ed4d77de2bb45457c8beabe00dcf20c959b29d932ff7387db154.png | complex | <table><tr><td> </td><td> </td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Axial length (mm)</td><td>Age (years)</td><td>−0.007 (−0.012 to −0.003)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.111 (0.035 to 0.186)</td><td>0.004</td></tr><tr><td>... | <table><tr><td></td><td></td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Axial length (mm)</td><td>Age (years)</td><td>−0.007 (−0.012 to −0.003)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.111 (0.035 to 0.186)</td><td>0.004</td></tr><tr><td>Education (Each year in... | <table><tr><td></td><td></td><td>Coefficient (95%CI of coefficient)</td><td>P-value</td></tr><tr><td rowspan="5">Anterior Chamber depth (mm)</td><td>Age (years)</td><td>−0.013 (−0.014 to −0.012)</td><td><0.001</td></tr><tr><td>Sex (male/female)</td><td>0.038 (0.012 to 0.064)</td><td>0.004</td></tr><tr><td>Education (Ea... |
bf800c00b2ac368a62a6678739240414350244d1f5038148d4e01eddcf770740.png | complex | <table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>−80</td><td>−60</td><td>−40</td><td>−20</td><td>0</td><td>20</td><td>40</td></tr><tr><td colspan="8">Pitch experiment</td></tr><tr><td>Qualitative descriptions</td><td>11</td><td>12</td><td>12</td><td>11</t... | <table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>−80</td><td>−60</td><td>−40</td><td>−20</td><td>0</td><td>20</td><td>40</td></tr><tr><td colspan="8">Pitch experiment</td></tr><tr><td>Qualitative descriptions</td><td>11</td><td>12</td><td>12</td><td>11</td><td>12</td><td>11</td>... | <table><tr><td></td><td colspan="7">Target head angle (degrees)</td></tr><tr><td></td><td>−80</td><td>−60</td><td>−40</td><td>−20</td><td>0</td><td>20</td><td>40</td></tr><tr><td>‐phase</td><td>/A</td><td>N/A</td><td></td><td></td><td>10</td><td>8</td><td>4</td></tr><tr><td>OF, out‐phase</td><td>N/A</td><td>N/A</td><td... |
bf37ad9e9e4039e88668875f19c55b4835ea361c8a145d0b62905c1e2b8f8c41.png | complex | <table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>New MDR patients (<i>n</i> = 5)</td><td>0 (0)</td>... | <table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>New MDR patients (n = 5</td><td>0</td><td>0 (</td>... | <table><tr><td></td><td>Ofloxacin</td><td colspan="2">Injectable drugs</td><td>TotalResistance to either Fluoroquinolone or injectable drugsN (%)</td></tr><tr><td></td><td>OfloxacinR, n (%)</td><td>KanamycinR, n (%)</td><td>CapreomycinR, n (%)</td><td></td></tr><tr><td>)</td><td> (0)</td><td>0)</td><td></td><td></td></... |
7445c6d458607ed471eee32dc6a2b7c3909b01e5ae51af2ee66864c764908539.png | simple | <table><tr><td>Ectoparasite</td><td> Postlactating females</td><td> Nonreproductive females</td></tr><tr><td></td><td>(<i>n</i> = 17)</td><td>(<i>n</i> = 97)</td></tr><tr><td><i>Spinturnix americanus</i></td><td>41.2%, 0.5 (0.7, 0–2)</td><td>38%, 0.7 (1.2, 0–5)</td></tr><tr><td><i>Myodopsylla insignis</i></... | <table><tr><td>Ectoparasite</td><td>Postlactating females</td></tr><tr><td></td><td>(n = 17)</td></tr><tr><td>Spinturnix americanus</td><td>41.2%, 0.5 (0.7, 0–2)</td></tr><tr><td>Myodopsylla insignis</td><td>47.1%, 1.1 (1.6, 0–5)</td></tr><tr><td>Macronyssus crosbyi</td><td>0</td></tr><tr><td>Cimex adjunctus</td><td>0<... | <table><tr><td>Nonreproductive females</td></tr><tr><td>(n = 97)</td></tr><tr><td>38%, 0.7 (1.2, 0–5)</td></tr><tr><td>32%, 0.7 (1.3, 0–7)</td></tr><tr><td>7.2%, 0.1 (0.3, 0–2)</td></tr><tr><td>0</td></tr><tr><td>1%, 0.02 (0.2, 0–2)</td></tr><tr><td>1%, 0.02 (0.2, 0–2)</td></tr><tr><td>66%, 1.5 (1.7, 0–5)</td></tr></ta... |
f23c799c1365bc27ce9d836632777589d275cc3664f9220d18148008638b19ad.png | complex | <table><tr><td>Finding</td><td>Illustrating data</td></tr><tr><td>Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily</td><td><i>Case D</i>: ‘The long term viability is very, very strong, it's viewed as an essential service, the pat... | <table><tr><td>Finding</td></tr><tr><td>Localized changes, with minimal impact on wider clinical systems or resource-allocation decisions, may be sustained relatively easily</td></tr><tr><td rowspan="2">Where impact on wider clinical systems and resource-allocation decisions is present, embedding the organizational inn... | <table><tr><td>Illustrating data</td></tr><tr><td>Case D: ‘The long term viability is very, very strong, it's viewed as an essential service, the patients need to be seen by a [clinical specialist in the mainstream clinical area] and they need to be seen by a geneticist, so they either come to our clinic or they get pu... |
7d4a134bcacd225568c66932266fcabfe2ead6f8e98f1017f546a1dc94d55489.png | simple | <table><tr><td><i>No.</i></td><td><i>Themes</i></td><td><i>OSPE</i></td><td><i>OSCE</i></td><td><i>Frequency</i></td><td><i>Total</i></td></tr><tr><td>1.</td><td><i>Curriculum</i></td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> </td><td> Syllabus</td><td>+</td><td>++</td><td>3</td><td>7</td></tr><tr><td> </td... | <table><tr><td>No.</td><td>Themes</td><td>OSPE</td><td>OSCE</td><td>Frequency</td></tr><tr><td>1.</td><td>Curriculum</td><td></td><td></td><td></td></tr><tr><td></td><td>Syllabus</td><td>+</td><td>++</td><td>3</td></tr><tr><td></td><td>Repetition</td><td>+++</td><td>+</td><td>4</td></tr><tr><td></td><td></td><td></td><... | <table><tr><td>Total</td></tr><tr><td></td></tr><tr><td>7</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>12</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>6</td></tr><tr><td></td></tr><tr><td></td></tr><tr><td>4</td></tr><tr><td></td></tr><tr><td></td></... |
17029d86268870618e765d54bc7a1f76d35470882b42caa5076bbf5e9da712a2.png | complex | <table><tr><td></td><td colspan="3">Intention to treat</td><td colspan="3">Modified intention to treat</td></tr><tr><td></td><td>Antibiotic treatmentn = 22</td><td>No antibiotic treatmentn = 36</td><td><i>P </i>value</td><td>Antibiotic treatmentn = 18</td><td>No antibiotic treatmentn = 26</td><td><i>P </i>value</td></t... | <table><tr><td></td><td colspan="3">Intention to treat</td><td colspan="3">Modified intention to treat</td></tr><tr><td></td><td>Antibiotic treatmentn = 22</td><td>No antibiotic treatmentn = 36</td><td>P value</td><td>Antibiotic treatmentn = 18</td><td>No antibiotic treatmentn = 26</td><td>P value</td></tr><tr><td>Trac... | <table><tr><td>Other infections</td><td>0 (0)</td><td>6 (16)</td><td>0.073</td><td>0 (0)</td><td>0 (0)</td><td>NA</td></tr><tr><td>Antibiotic treatment after day 8 post-random assignment</td><td>6 (27)</td><td>8 (22)</td><td>0.756</td><td>3 (16)</td><td>5 (19)</td><td>>0.999</td></tr></table> |
1419b03df6458ee6e5d54931cd53374526853019363efc48b43f7227b0f583df.png | simple | <table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Huancayo, 2000</td><td>47.1 (40.9–53.5) (n = 963)</td><td>18.1 (13.6–23.6) (n = 429)</td>... | <table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Huancayo, 2000</td><td>47.1 (40.9–53.5) (n = 963)</td><td>18.1 (13.6–23.6) (n = 429)</td><td>29.7 (24... | <table><tr><td>Site</td><td>Ever smoked cigarettes, even one or two puffs</td><td>Ever smokers who initiated smoking before age 10</td><td>Never smokers susceptible to initiate smoking in the next year</td></tr><tr><td>Tarapoto, 2000</td><td>42.5 (35.6–49.8) (n = 750)</td><td>10.9 (7.6–15.3) (n = 305)</td><td>19.2 (15.... |
c17e4be7f9acfa1b3f15c820171fd26dc5f15eb17837d4ffbf070c9ba7d4ae26.png | complex | <table><tr><td></td><td colspan="2">Response rate</td><td colspan="2">NR</td></tr><tr><td></td><td>Prosody+</td><td>Prosody−</td><td>Prosody+</td><td>Prosody−</td></tr><tr><td>Healthy controls (CI 95%)</td><td>96 ± 4 (94, 98)</td><td>84 ± 7 (81, 87)</td><td>3 ± 4(2, 2)</td><td>10 ± 7(7, ... | <table><tr><td></td><td colspan="2">Response rate</td><td colspan="2">NR</td></tr><tr><td></td><td>Prosody+</td><td>Prosody−</td><td>Prosody+</td><td>Prosody−</td></tr></table> | <table><tr><td>Healthy controls (CI 95%)</td><td>96 ± 4 (94, 98)</td><td>84 ± 7 (81, 87)</td><td>3 ± 4(2, 2)</td><td>10 ± 7(7, 14)</td></tr><tr><td>Patients with schizophrenia (CI 95%)</td><td>78 ± 16 (70, 86)</td><td>58 ± 19 (49, 67)</td><td>22 ± 17 (14, 30)</td><td>37 ± 20 (28, 47)</td></tr></table> |
516ae0c6d76f7b9a6d5345af55af644c356dc2d99da3876cc8b4a8a3eada9544.png | simple | <table><tr><td>Clinical trials</td><td>Interventions</td><td>URL</td></tr><tr><td>124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study</td><td>Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)</td><td>https://ClinicalTrials.... | <table><tr><td>Clinical trials</td><td>Interventions</td><td>URL</td></tr><tr><td>124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patie</td><td></td><td>https://ClinicalTrials.gov/show/NCT01583842</td></tr></table> | <table><tr><td>nts With Neuroblastoma: A Pilot Study</td><td>Radiation: 124I-MIBG (no-carrier added)Radiation: 124I-MIBG (carrier added)</td><td></td></tr><tr><td>European Low and Intermediate Risk Neuroblastoma Protocol (low and intermediate pediatric NB and neonatal suprarenal masses)</td><td>Drug: chemotherapy</td><... |
021dbabad68a7ad792b14d061ed0531423bd4869aade3007fa149daf2b45e637.png | complex | <table><tr><td>Capacity areas/skills for HPSR+A</td><td>Proportion of staff requiring additional training (n = 123), n (%)</td></tr><tr><td>HPSR+A technical skills and conceptual underpinnings,</td><td></td></tr><tr><td> e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching</td><td>101 (82... | <table><tr><td>Capacity areas/skills for HPSR+A</td></tr><tr><td>HPSR+A technical skills and conceptual underpinnings,</td></tr><tr><td>e.g. what is HPSR+A and what constitutes HPSR+A approaches to research and teaching</td></tr><tr><td>HPSR+A research and writing</td></tr><tr><td>Writing research methodologies</td></t... | <table><tr><td>Proportion of staff requiring additional training (n = 123), n (%)</td></tr><tr><td></td></tr><tr><td>101 (82.0)</td></tr><tr><td></td></tr><tr><td>84 (68.0)</td></tr><tr><td></td></tr><tr><td>80 (65.0)</td></tr><tr><td>78 (63.0)</td></tr><tr><td></td></tr><tr><td>92 (75.0)</td></tr><tr><td>94 (76.0)</td... |
5f878d53217ae4423cf49df0789c433e72e7fe65c36e96a96f1865433f9ec60a.png | simple | <table><tr><td>Variable</td><td>n</td><td>%</td><td>SE (<i>P</i>)</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td> Male</td><td>207</td><td>62.9</td><td>2.67</td></tr><tr><td> Female</td><td>121</td><td>36.8</td><td>2.66</td></tr><tr><td>Age (y)</td><td></td><td></td><td></td></tr><tr><td> <40</td><... | <table><tr><td>Variable</td><td>n</td><td>%</td><td>SE (P)</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>207</td><td>62.9</td><td>2.67</td></tr><tr><td>Female</td><td>121</td><td>36.8</td><td>2.66</td></tr><tr><td>Age (y)</td><td></td><td></td><td></td></tr><tr><td><40</td><td>11</td><td... | <table><tr><td>Marital status</td><td></td><td></td><td></td></tr><tr><td>Single</td><td>14</td><td>4.3</td><td>1.12</td></tr><tr><td>Married</td><td>264</td><td>8.2</td><td>1.51</td></tr><tr><td>Other</td><td>16</td><td>4.8</td><td>1.18</td></tr><tr><td>Unknown</td><td>12</td><td>3.6</td><td>1.03</td></tr><tr><td>Ethn... |
4a9197a72bdd3845b64a72d3e5eabc783c3061d278531812f891899b5df9f5d0.png | complex | <table><tr><td rowspan="2">Variables</td><td>Cases</td><td>Controls</td><td>Adjusted OR ratio</td><td rowspan="2">P value</td></tr><tr><td>No. (%)</td><td>No. (%)</td><td>(95% Cl)</td></tr><tr><td>Family size (mean 95% Cl)</td><td>5.8(5.3-6.4)</td><td>4.8(4.4-5.1)</td><td>1.359(1.026-1.799)</td><td>0.032</td></tr><tr><... | <table><tr><td rowspan="2">Variables</td><td>Cases</td><td>Controls</td><td>Adjusted OR ratio</td><td rowspan="2">P value</td></tr><tr><td>No. (%)</td><td>No. (%)</td><td>(95% Cl)</td></tr><tr><td>Family size (mean 95% Cl)</td><td>5.8(5.3-6.4)</td><td>4.8(4.4-5.1)</td><td>1.359(1.026-1.799)</td><td>0.032</td></tr><tr><... | <table><tr><td>Ref. (No)</td><td>53(58.9%)</td><td>150(77.7%)</td><td>1</td><td></td></tr><tr><td>Sleeping outside the house under bed net</td><td>16(17.8%)</td><td>118(61.1%)</td><td>0.093(0.024-0.357)</td><td>0.001</td></tr><tr><td>Ref. (without bed net)</td><td>74(82.2%)</td><td>75(38.9%)</td><td>1</td><td></td></tr... |
e7b94328afe7a4805b2aa03fe1a4f0ef063b12c90fda2ae99a3dbaee3c58dee9.png | complex | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg<sup>−1</sup></td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean ± SEM</td></tr><tr><td>Control</td><td>0.3 mL</td><td>51.73 ± 2.35</td></tr><tr><td>Indomethacin</td><td>10</td><td>19.82 ± 2.52 (61.68)<sup>b</su... | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg−1</td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean ± SEM</td></tr><tr><td>Control</td><td>0.3 mL</td><td>51.73 ± 2.35</td></tr><tr><td>Indomethacin</td><td>10</td><td>19.82 ± 2.52 (61.68)b</td></tr><tr><td>EEDR</td><td>100</td><t... | <table><tr><td rowspan="2">Treatment</td><td rowspan="2">Dose mg kg−1</td><td>Cotton pellet granuloma</td></tr><tr><td>Weight of pellets Mean ± SEM</td></tr><tr><td></td><td>00</td><td>)b</td></tr><tr><td>EEDR</td><td>400</td><td>29.77 ± 3.76 (42.44)a</td></tr></table> |
38faa325fa1ef7142f47f0185c8d79492a36b15bce9c5663158995af6ed5bdfb.png | simple | <table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(<i>n </i>= 20)</td><td>(<i>n </i>= 8)</td><td>(<i>n </i>= 12)</td><td></td></tr><tr><td>Age (years)</td><td>77 [65-82]</td><td>75 [70-80]</td><td>78 [65-84]</td><td>0.4</td></tr><tr><td>Female se... | <table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(n = 20)</td><td>(n = 8)</td><td>(n = 12)</td><td></td></tr><tr><td>Age (years)</td><td>77 [65-82]</td><td>75 [70-80]</td><td>78 [65-84]</td><td>0.4</td></tr><tr><td>Female sex, n (%)</td><td>18 (... | <table><tr><td>Characteristic</td><td>All</td><td>LGE [IQR]</td><td>Non-LGE [IQR]</td><td>p value</td></tr><tr><td></td><td>(n = 20)</td><td>(n = 8)</td><td>(n = 12)</td><td></td></tr><tr><td>CHF</td><td>3 (15%)</td><td>2 (25%)</td><td>1 (8%)</td><td>0.5</td></tr><tr><td>Cardiogenic shock</td><td>3 (15%)</td><td>3 (38%... |
69f4185d1b5e258904f268af7655885a9394ac5a7843f08cf12409ac9d168424.png | simple | <table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Biomedical</td><td>Absence of multi-morbidity</td><td>[6]</td></tr><tr><td>Psycho-Cognitive</td><td>Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience</td><td... | <table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Biomedical</td><td>Absence of multi-morbidity</td><td>[6]</td></tr><tr><td>Psycho-Cognitive</td><td>Absence of depression, absence of anxiety, no cognitive impairment, regular functioning, quality of life, resilience</td><td... | <table><tr><td>Successful Aging Approach</td><td>Definition</td><td>References</td></tr><tr><td>Lay View Approach</td><td>Presence of well-being, good self perceived health</td><td>[8,12]</td></tr><tr><td>Combined Approach</td><td>Optimal functioning</td><td>[6,12]</td></tr></table> |
9fe8545e6152550dbaaa8b03f9f6ceee74e41b643f3343d6109e9e806b5cae87.png | complex | <table><tr><td>Country and Year</td><td>Criteria used for identifying asymptomatic malaria cases</td><td>Study subjects, sample size</td><td>Follow-up protocol and duration</td><td>Ref.</td></tr><tr><td colspan="5">Africa</td></tr><tr><td>Gabon, 2003</td><td>No clinical symptoms of malaria with a <i>P. falciparum </i>p... | <table><tr><td>Country</td><td>Crite</td><td>Study subject</td><td>Follow-up protocol and durati</td><td>Ref</td></tr></table> | <table><tr><td> and Year</td><td>ria used for identifying asymptomatic malaria cases</td><td>s, sample size</td><td>on</td><td>.</td></tr><tr><td colspan="5">Africa</td></tr><tr><td>Gabon, 2003</td><td>No clinical symptoms of malaria with a P. falciparum positive blood smear, asymptomatic for at least 5 days during fol... |
36f88ed582bd0bdf0254df192a761747cd5449c424e4e174da31d02879d2fe58.png | complex | <table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones ± (mm)<sup>1</sup></td></tr><tr><td><i>E. coli</i>CCMB261</td><td><i>S. aureus</i> CCMB262</td><td><i>S. aureus</i> CCMB263</td><td><i>P. aeruginosa</i>CCMB268</td><td><i>C. albicans</i>CCMB286</td><td><i>C. parapsilosis</i>CCMB288</td></tr><t... | <table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones ± (mm)1</td></tr><tr><td>E. coliCCMB261</td><td>S. aureus CCMB262</td><td>S. aureus CCMB263</td><td>P. aeruginosaCCMB268</td><td>C. albicansCCMB286</td><td>C. parapsilosisCCMB288</td></tr><tr><td>L. alnifolia leaves</td><td>R</td><td>10.2 ± 1.3</td... | <table><tr><td rowspan="2">Samples</td><td colspan="6">Inhibition zones ± (mm)1</td></tr><tr><td>E. coliCCMB261</td><td>S. aureus CCMB262</td><td>S. aureus CCMB263</td><td>P. aeruginosaCCMB268</td><td>C. albicansCCMB286</td><td>C. parapsilosisCCMB288</td></tr><tr><td>L. thymoides flowers</td><td>R</td><td>8.5 ± 1.5</t... |
eb5e2e7f59bdde7d9732367d5a69d92602999495c2029b1eced30faab504021f.png | complex | <table><tr><td colspan="2">Characteristics</td><td>n (<i>N</i> = 157)</td><td>%</td></tr><tr><td rowspan="4">Age</td><td><19 years</td><td>3</td><td>1.9</td></tr><tr><td>20–24 years</td><td>104</td><td>66.3</td></tr><tr><td>25–29 years</td><td>47</td><td>29.9</td></tr><tr><td>>30 years</td><td>3</td><... | <table><tr><td colspan="2">Characteristics</td><td>n (N = 157)</td><td>%</td></tr><tr><td rowspan="4">Age</td><td><19 years</td><td>3</td><td>1.9</td></tr><tr><td>20–24 years</td><td>104</td><td>66.3</td></tr><tr><td>25–29 years</td><td>47</td><td>29.9</td></tr><tr><td>>30 years</td><td>3</td><td>1.9</td></tr><tr><td r... | <table><tr><td>Educational level</td><td>Doctor degree</td><td>23</td><td>14.6</td></tr><tr><td rowspan="5">Work experience in the health sector</td><td><6 months</td><td>52</td><td>33.1</td></tr><tr><td>6–12 months</td><td>53</td><td>33.8</td></tr><tr><td>12–24 months</td><td>44</td><td>28.0</td></tr><tr><td>24–36 mon... |
7218de6fc23796deb05334090941df9b8cdd00cda7544243685e57655abb886d.png | simple | <table><tr><td>Neonatal characteristic </td><td>Newborn-monotherapy dyadsMean (SE) or <i>n</i> (%)</td><td>Newborn-triple therapy dyadsMean (SE) or <i>n</i> (%)</td><td><i>p</i> value</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>45 (53%)</td><td>18 (49%)</td><td>NS</td></tr><tr><... | <table><tr><td>Neonatal characteristic</td><td>Newborn-monotherapy dyadsMean (SE) or n (%)</td><td>Newborn-triple therapy dyadsMean (SE) or n (%)</td><td>p value</td></tr><tr><td>Gender</td><td></td><td></td><td></td></tr><tr><td>Male</td><td>45 (53%)</td><td>18 (49%)</td><td>NS</td></tr><tr><td>Gestational age (weeks)... | <table><tr><td>Positive</td><td>10 (12%)</td><td>23 (62%)</td><td><0.05</td></tr><tr><td>NICU admission</td><td>19 (22%)</td><td>20 (54%)</td><td><0.01</td></tr><tr><td>Length of stay in hospital (days)∗</td><td>3 (0.5)</td><td>8 (2)</td><td><0.05</td></tr><tr><td>CPS involved</td><td>15 (18%)</td><td>26 (70%)</td><td>... |
19012ee9c3c84b5d7b35e1a9602eb0db9b9953ee8d41169cf64f8ceb01e5ffd2.png | simple | <table><tr><td>ARV site</td><td>Total number of patients</td></tr><tr><td>Thamaga primary hospital</td><td>1646</td></tr><tr><td>Nkoyaphiri clinic</td><td>1726</td></tr><tr><td>Gabane clinic</td><td>392</td></tr><tr><td>Thamaga clinic</td><td>114</td></tr><tr><td>Mmankgodi clinic</td><td>70</td></tr><tr><td>Kopong clin... | <table><tr><td>ARV site</td></tr><tr><td>Thamaga primary hospital</td></tr><tr><td>Nkoyaphiri clinic</td></tr><tr><td>Gabane clinic</td></tr><tr><td>Thamaga clinic</td></tr><tr><td>Mmankgodi clinic</td></tr><tr><td>Kopong clinic</td></tr><tr><td>Mmopane clinic</td></tr><tr><td>Total</td></tr></table> | <table><tr><td>Total number of patients</td></tr><tr><td>1646</td></tr><tr><td>1726</td></tr><tr><td>392</td></tr><tr><td>114</td></tr><tr><td>70</td></tr><tr><td>200</td></tr><tr><td>120</td></tr><tr><td>4268</td></tr></table> |
cd8d3d47aea593f5fe2a9aee7ecef03759ea4d2e77f05fb28ec49adf7857e21a.png | complex | <table><tr><td rowspan="2">Group</td><td rowspan="2">No. mice</td><td colspan="2">Vaccine and administration</td><td rowspan="2">Anti‐HCV Abs</td><td colspan="4">Days post‐prime</td></tr><tr><td>Prime</td><td>2xboost</td><td>0</td><td>14</td><td>28</td><td>42</td></tr><tr><td></td><td></td><td></td><td></td... | <table><tr><td>Group</td><td>No. mice</td><td colspan="2">Vaccine and administration</td><td>Anti‐HCV Abs</td><td colspan="4">Days post‐prime</td></tr></table> | <table><tr><td>Group</td><td>No. mice</td><td>Prime</td><td>2xboost</td><td>Anti‐HCV Abs</td><td>0</td><td>14</td><td>28</td><td>42</td></tr><tr><td></td><td></td><td></td><td></td><td>Serum IgM</td><td>0/5</td><td>0/5</td><td>0/5</td><td>0/5</td></tr><tr><td>0</td><td>5</td><td></td><td></td><td>Serum IgG</td><td>0/5<... |
41a4403dd2ac23791690183e73205a590b7829791e63bf352de8d13363a6539c.png | complex | <table><tr><td>species</td><td>factors associated with chick-a-dee call variation</td><td>references</td></tr><tr><td rowspan="4">black-capped chickadee <i>Poecile atricapillus</i></td><td>species</td><td>[48,68–70]</td></tr><tr><td>flock</td><td>[71,72]</td></tr><tr><td>individual</td><td>[73]</td></tr><tr><td>p... | <table><tr><td>species</td><td>factors associated with chick-a-dee call variation</td><td>references</td></tr><tr><td rowspan="4">black-capped chickadee Poecile atricapillus</td><td>species</td><td>[48,68–70]</td></tr><tr><td>flock</td><td>[71,72]</td></tr><tr><td>individual</td><td>[73]</td></tr><tr><td>predator</td><... | <table><tr><td rowspan="2">ntain chickadee P. gambeli</td><td>ndividual</td><td>]</td></tr><tr><td>flight</td><td>[91]</td></tr><tr><td rowspan="2">tufted titmouse Baeolophus bicolor</td><td>individual</td><td>[92]</td></tr><tr><td>predator</td><td>[83,93,94]</td></tr><tr><td>crested tit Lophophanes cristatus</td><td>p... |
9777079b89514aa189c6b34ee562784d3e726744c8a149303c9f2b3addc43f86.png | simple | <table><tr><td> </td><td>n</td><td>%*</td></tr><tr><td>Number of patients</td><td>635</td><td> </td></tr><tr><td>Median age at time of VIT-initiation (years) (range)</td><td>39</td><td>(5–77)</td></tr><tr><td>Male/female</td><td>322/313</td><td> </td></tr><tr><td>Results of allergy testing</td><td> </td><td> </td... | <table><tr><td></td></tr><tr><td>Number of patients</td></tr><tr><td>Median age at time of VIT-initiation (years) (range)</td></tr><tr><td>Male/female</td></tr><tr><td>Results of allergy testing</td></tr><tr><td>Vespula (vulgaris/germanica) mono sensitization</td></tr><tr><td>Honey bee (Apis mellifera) mono sensitizati... | <table><tr><td>n</td><td>%*</td></tr><tr><td>635</td><td></td></tr><tr><td>39</td><td>(5–77)</td></tr><tr><td>322/313</td><td></td></tr><tr><td></td><td></td></tr><tr><td>251</td><td>39.5</td></tr><tr><td>33</td><td>5.2</td></tr><tr><td>351</td><td>55.3</td></tr><tr><td></td><td></td></tr><tr><td>8</td><td>1.3</td></tr... |
3d5765a99720f2f2359a28bc08895fb5fe8b3e51cce6b07f66df889ce7731228.png | simple | <table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>AOSD</td><td>20/35</td><td>14</td><td>3</td><td>1</td><td>0</td><td... | <table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>AOSD</td><td>20/35</td><td>14</td><td>3</td><td>1</td><td>0</td><td... | <table><tr><td>Disease</td><td>No. withdrawals/treated patients</td><td>Inefficacy or loss of efficacy</td><td>Adverse event</td><td>Persistent remission</td><td>On-demand treatment</td><td>Patient request</td><td>Switch to canakinumab</td></tr><tr><td>Schnitzler’s syndrome</td><td>3/7</td><td>1</td><td>2</td><td>0</td... |
7ea05d0d83e6c02a09bc085c482e6576242d4223ea04c7645ed06d19d7128a77.png | complex | <table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td><i>N</i></td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td>RT negative</t... | <table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td>N</td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td>RT negative</td><td>1... | <table><tr><td></td><td colspan="2">Total</td><td colspan="2">Sham</td><td colspan="2">0.5 mA</td><td colspan="2">1.0 mA</td><td colspan="2">1.5 mA</td></tr><tr><td>N</td><td colspan="2">87</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">22</td><td colspan="2">21</td></tr><tr><td></td><td>.66</td><td>... |
28a316edd201c7a7c77a2c2ea7e4df584d3345c46be8e67522463e66b8c9b801.png | complex | <table><tr><td></td><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>Adult</td><td>No HCE</td><td>0.726</td><td>(0.721, 0.730)</td><td>0.624</td><td>(0.619, 0.631)</td></tr><tr><td></td><td>HCE</td><td>0.772</td>... | <table><tr><td></td><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>Adult</td><td>No HCE</td><td>0.726</td><td>(0.721, 0.730)</td><td>0.624</td><td>(0.619, 0.631)</td></tr><tr><td></td><td>HCE</td><td>0.772</td>... | <table><tr><td></td><td colspan="2">RF</td><td colspan="2">PCVA</td></tr><tr><td></td><td>Median</td><td>95% UI</td><td>Median</td><td>95% UI</td></tr><tr><td>HCE</td><td>0.726</td><td>(0.717, 0.734)</td><td>0.733</td><td>(0.719, 0.743)</td></tr></table> |
acf975ad1fdf4552d8e866485a621850385bd0728be5f4c8dd610e35e9e9ee3f.png | complex | <table><tr><td> </td><td colspan="2">5-HT</td><td colspan="2">Motilin</td><td colspan="2">VIP</td><td colspan="2">Somatostatin</td></tr><tr><td>TDCA</td><td>−0.07</td><td>0.76</td><td>0.11</td><td>0.65</td><td>0.23</td><td>0.32</td><td>0.19</td><td>0.43</td></tr><tr><td>TCA</td><td>−0.33</td><td>0.15</td><t... | <table><tr><td></td><td colspan="2">5-HT</td><td colspan="2">Motilin</td><td colspan="2">VIP</td><td colspan="2">Somatostatin</td></tr><tr><td>TDCA</td><td>−0.07</td><td>0.76</td><td>0.11</td><td>0.65</td><td>0.23</td><td>0.32</td><td>0.19</td><td>0.43</td></tr><tr><td>TCA</td><td>−0.33</td><td>0.15</td><td>−0.02</td><... | <table><tr><td>TLCA</td><td>−0.06</td><td>0.81</td><td>−0.10</td><td>0.69</td><td>0.06</td><td>0.80</td><td>−0.17</td><td>0.48</td></tr></table> |
48f30b687315d295c78ee3ac06aa071a6572227342e5fb2de4afc334919f27bd.png | simple | <table><tr><td>Variable</td><td>Elderly</td><td>Middle aged</td><td>Young</td><td>P value</td></tr><tr><td>TChol</td><td>79(44%)</td><td>161 (42%)</td><td>11(31%)</td><td>0.3</td></tr><tr><td>HDL-C</td><td>98(54%)</td><td>205(53%)</td><td>15(41%)</td><td>0.3</td></tr><tr><td>LDL-C</td><td>129 (71%)</td><td>286(74%)</td... | <table><tr><td>Variable</td><td>Elderly</td><td>Middle aged</td><td>Young</td><td>P value</td></tr><tr><td>TChol</td><td>79(44%)</td><td>161 (42%)</td><td>11(31%)</td><td>0.3</td></tr><tr><td>HDL-C</td><td>98(54%)</td><td>205(53%)</td><td>15(41%)</td><td>0.3</td></tr><tr><td>LDL-C</td><td>129 (71%)</td><td>286(74%)</td... | <table><tr><td>TG</td><td>18 (10%)</td><td>56(15%)</td><td>1(2%)</td><td>0.05</td></tr></table> |
28c0fc02095e218ad072c52998949988ba8ed70f0416544dd8beaa516ed6c82f.png | simple | <table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Number</td><td>20</td><td>8</td></tr><tr><td>Age</td><td>49.4 ± 3.9</td><td>43.0 ± 4.8</td></tr><tr><td>Male:Female</td><td>4:16</td><td>4:4</td></tr><tr><td>Disease duration</td><td>8.1 ± 2.0</td><td>9.9 ± 3.7</td></tr><tr><td>Re... | <table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Number</td><td>20</td><td>8</td></tr></table> | <table><tr><td>Patients</td><td>NMO/NMOSD</td><td>MS</td></tr><tr><td>Age</td><td>49.4 ± 3.9</td><td>43.0 ± 4.8</td></tr><tr><td>Male:Female</td><td>4:16</td><td>4:4</td></tr><tr><td>Disease duration</td><td>8.1 ± 2.0</td><td>9.9 ± 3.7</td></tr><tr><td>Relapses in the last 2 years</td><td>1.2 ± 0.3</td><td>2.3 ± 0.5</t... |
b7dd328c83bb11b7a92052517ea63c053e8cd0c65d401134a2c05c2117f45829.png | complex | <table><tr><td colspan="2">% Change in relative probability of delivery with a 5-min increase in travel time<sup>a</sup></td></tr><tr><td>Delivery at any facility</td><td>−30.0</td></tr><tr><td>Public facility delivery</td><td>−28.2</td></tr><tr><td>Private facility delivery</td><td>−32.9</td></tr><tr... | <table><tr><td>% Change in relative probability of delivery with a 5-min increase in travel timea</td></tr><tr><td>Delivery at any facility</td></tr><tr><td>Public facility delivery</td></tr><tr><td>Private facility delivery</td></tr><tr><td>NGO facility delivery</td></tr></table> | <table><tr><td>% Change in relative probability of delivery with a 5-min increase in travel timea</td></tr><tr><td>−30.0</td></tr><tr><td>−28.2</td></tr><tr><td>−32.9</td></tr><tr><td>−28.6</td></tr></table> |
b6da2883ffba25126555130e59bd35e0c11c1afb0e58749b9bfe9a128a6e18c9.png | complex | <table><tr><td>Cell Types</td><td>Species/Cell Lines</td><td colspan="2">Melotonin Effects</td><td>Receptor Types</td><td>Melatonin Concentrations</td><td>References</td></tr><tr><td>Leydig cell</td><td>mouse</td><td>Inhibition of steroid production</td><td>Inhibition of <i>StAR</i> protein expression </td><td><i>Mt1 a... | <table><tr><td>Cell Types</td><td>Species/Cell Lines</td><td colspan="2">Melotonin Effects</td><td>Receptor Types</td><td>Melatonin Concentrations</td><td>References</td></tr><tr><td>Leydig cell</td><td>mouse</td><td>Inhibition of steroid production</td><td>Inhibition of StAR protein expression</td><td>Mt1 and/or Mt2</... | <table><tr><td></td><td></td><td></td><td>nsulin-stimulated lactate generation</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Stimulation of GLUT1 protein expression and glucose consumption</td><td></td><td>1 mM</td><td>[33]</td></tr><tr><td></td><td></td><td></td><td>Inhibition of LDH p... |
d898a7fdbeed8809f38d13d3b062e1f00622831fc16a569b31278c92ebc5e57b.png | simple | <table><tr><td>Demographics</td><td> </td></tr><tr><td>Mean age, years (range)</td><td>32 (11–55)</td></tr><tr><td>Male : female</td><td>43 : 8 </td></tr><tr><td>Transfusion requirements, units (range)</td><td>7 (3–12) </td></tr></table> | <table><tr><td>Demographics</td><td></td></tr><tr><td>Mean age, years (range)</td><td>32 (11–55)</td></tr><tr><td>Male : female</td><td>43 : 8</td></tr></table> | <table><tr><td>Demographics</td><td></td></tr><tr><td>Transfusion requirements, units (range)</td><td>7 (3–12)</td></tr></table> |
5679396b595d8489393511235bd725ada18e046a2cdaecc9e3c15ee35a8babca.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">Intervention group</td><td colspan="3">Control group</td><td rowspan="2"><i>P</i> Value<sup>*</sup></td></tr><tr><td>T1<sup>a</sup></td><td>T2<sup>a</sup></td><td>T3<sup>a</sup></td><td>T1<sup>a</sup></td><td>T2<sup>a</sup></td><td>T3<sup>a</sup></td></tr><tr><td>Rural (n... | <table><tr><td rowspan="2"></td><td colspan="3">Intervention group</td><td colspan="3">Control group</td><td rowspan="2">P Value*</td></tr><tr><td>T1a</td><td>T2a</td><td>T3a</td><td>T1a</td><td>T2a</td><td>T3a</td></tr><tr><td>Rural (n = 1539)</td><td>0.11 ± 0.20</td><td>0.15 ± 0.23</td><td>0.15 ± 0.24</td><td>0.11 ± ... | <table><tr><td>1512)</td><td></td><td>23</td><td>6 ± 0.23</td><td></td><td>0.17 ± 0.27</td><td>.29</td><td>01</td></tr><tr><td>Elementary school (n = 2451)</td><td>0.09 ± 0.18</td><td>0.12 ± 0.21</td><td>0.13 ± 0.22</td><td>0.08 ± 0.18</td><td>0.12 ± 0.22</td><td>0.14 ± 0.22</td><td>< 0.001</td></tr><tr><td>Secondary s... |
0d9589ae9fe73710df5ce3f85b78b913668722358bb1226043fcdb482e4281ce.png | complex | <table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Pain</td><td>0.555</td><td>−0.162</td></tr><tr><td>Shortness of breath</td><td>0.497</td><td>−0.318</td></tr><tr><td>Weakness or lack of energy</td><td>0.547</td><td>−0.379</td></tr><tr><td>Naus... | <table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Pain</td><td>0.555</td><td>−0.162</td></tr><tr><td>Shortness of breath</td><td>0.497</td><td>−0.318</td></tr><tr><td>Weakness or lack of energy</td><td>0.547</td><td>−0.379</td></tr><tr><td>Nausea</td><td>0.251</... | <table><tr><td rowspan="2">Item</td><td colspan="2">Component</td></tr><tr><td>1</td><td>2</td></tr><tr><td>Poor appetite</td><td>0.398</td><td>−0.236</td></tr><tr><td>Constipation</td><td>0.305</td><td>−0.001</td></tr><tr><td>Mouth problems</td><td>0.558</td><td>−0.305</td></tr><tr><td>Drowsiness</td><td>0.433</td><td... |
fc67abf3f14a53b7422e1b62d224a36bce741327aea2ccd9af1c7877836a32dd.png | simple | <table><tr><td>Variable</td><td>Current contraceptive use n (%)</td><td>Unadjusted RR (95% CI)</td><td>Adjusted RR (95% CI)</td></tr><tr><td>Age (completed years)</td><td></td><td><i>p</i> = 0.45</td><td></td></tr><tr><td> 13–19</td><td>9 (36.0)</td><td>1</td><td>−</td></tr><tr><td> 20–29</td><td>154 ... | <table><tr><td>Variable</td><td>Current contraceptive use n (%)</td><td>Unadjusted RR (95% CI)</td><td>Adjusted RR (95% CI)</td></tr><tr><td>Age (completed years)</td><td></td><td>p = 0.45</td><td></td></tr><tr><td>13–19</td><td>9 (36.0)</td><td>1</td><td>−</td></tr><tr><td>20–29</td><td>154 (50.8)</td><td>1.41 (0.83, ... | <table><tr><td>Yes</td><td>214 (70.9)</td><td>2.45 (2.04, 3.03)</td><td>1.91 (1.56, 2.33)</td></tr></table> |
1bc20d0031951ef0fda30b66a68626db9ed1b77bfa0eade7046ae6aad2daa7ec.png | complex | <table><tr><td colspan="3">Measurement</td><td colspan="2">Location</td><td>Data points</td><td>Sampling rate</td></tr><tr><td>Parameter</td><td>Method</td><td>Performed by</td><td>Laboratory</td><td>Office</td><td>d<sup>-1</sup> (overall)</td><td>s<sup>-1</sup></td></tr><tr><td colspan="7"><i>Physiological</i></td></t... | <table><tr><td colspan="3">Measurement</td><td colspan="2">Location</td><td>Data points</td><td>Sampling rate</td></tr><tr><td>Parameter</td><td>Method</td><td>Performed by</td><td>Laboratory</td><td>Office</td><td>d-1 (overall)</td><td>s-1</td></tr><tr><td colspan="7">Physiological</td></tr></table> | <table><tr><td>Sitting time</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.d</td></tr><tr><td>Physical activity</td><td>IPAQ-long</td><td>questionnaire - interview</td><td>x</td><td></td><td>1 (4)</td><td>n.a.d</td></tr><tr><td>Mental workload</td><td>NASA-TLX</td><td>q... |
ee6abc8a1f2d293c061321c6ff7fe9ce45cd866f8aa82ea96f66c308e4a2595f.png | simple | <table><tr><td>Patient type</td><td>RCTs n (%)</td></tr><tr><td>Medical/Surgical</td><td>106 (43)</td></tr><tr><td>Medical only</td><td>56 (23)</td></tr><tr><td> Bronchiolitis</td><td>16 (6)</td></tr><tr><td> Sepsis/Shock</td><td>13 (5)</td></tr><tr><td> Asthma</td><td>8 (3)</td></tr><tr><td> Other medical</td><td>19 (... | <table><tr><td>Patient type</td><td>RCTs n (%)</td></tr><tr><td>Medical/Surgical</td><td>106 (43)</td></tr><tr><td>Medical only</td><td>56 (23)</td></tr><tr><td>Bronchiolitis</td><td>16 (6)</td></tr><tr><td>Sepsis/Shock</td><td>13 (5)</td></tr><tr><td>Asthma</td><td>8 (3)</td></tr><tr><td>Other medical</td><td>19 (8)</... | <table><tr><td>Trauma/Burns only</td><td>26 (10)</td></tr><tr><td>Traumatic brain Injury</td><td>13 (5)</td></tr><tr><td>Burns</td><td>13 (5)</td></tr></table> |
ff0b45f13cd4381fb7232694c99357353fd58f7da8b6f9651e671860f73c4f82.png | simple | <table><tr><td></td><td>Neoadjuvant (<i>n</i> = 80)</td><td>Adjuvant (<i>n</i> = 90)</td><td><i>P</i></td></tr><tr><td>PHS (days)</td><td>11 (7–33)</td><td>11 (5–51)</td><td>0.920<sup>a</sup></td></tr><tr><td>PHS with complications (days)</td><td>15</td><td>17</td><td>0.503<sup>b</sup></td></tr><tr><td>PHS ... | <table><tr><td></td><td>Neoadjuvant (n = 80)</td><td>Adjuvant (n = 90)</td><td>P</td></tr><tr><td>PHS (days)</td><td>11 (7–33)</td><td>11 (5–51)</td><td>0.920a</td></tr><tr><td>PHS with complications (days)</td><td>15</td><td>17</td><td>0.503b</td></tr><tr><td>PHS without complications (days)</td><td>11</td><td>11</td>... | <table><tr><td>Patients with complications</td><td>15 (18.8%)</td><td>20 (22.2%)</td><td>0.704</td></tr><tr><td>Non-surgical complications</td><td></td><td></td><td></td></tr><tr><td>Pneumonia</td><td>1 (1.3%)</td><td>3 (3.3%)</td><td>0.623</td></tr><tr><td>Pleural effusion</td><td>0 (0.0%)</td><td>2 (2.2%)</td><td>0.4... |
8b98dd7edbd44c04f4a4a2f01e3eec938ea13e87e73b46e87b456a6c7d9757ba.png | complex | <table><tr><td> </td><td colspan="3">Pre-supplementation</td><td colspan="3">Post-supplementation</td></tr><tr><td>Measure</td><td>Subjects reporting GIT symptoms post-supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td><i>P </i>value</td><td>Subjects reporting GIT symptoms post- suppleme... | <table><tr><td></td><td colspan="3">Pre-supplementation</td><td colspan="3">Post-supplementation</td></tr><tr><td>Measure</td><td>Subjects reporting GIT symptoms post-supplement (mean)</td><td>Subjects GIT symptom free post-supplement (mean)</td><td>P value</td><td>Subjects reporting GIT symptoms post- supplement (mean... | <table><tr><td>Chalder fatigue scale</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total fatigue scores</td><td>14.2</td><td>11.8</td><td>ns</td><td>12.6</td><td>8.9</td><td>ns</td></tr><tr><td>Amino acids</td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><td rowspan="2"></td><... |
076a53d15ab6e74e8d04cd4a6802d4df7f10973e4d102359f6ea94419f09a38f.png | complex | <table><tr><td rowspan="2">Variable</td><td>Glaucoma group <i>n</i> = 8777</td><td>Control group <i>n</i> = 35,108</td><td rowspan="2"><i>p-</i>value</td></tr><tr><td><i>n</i> (%)</td><td><i>n</i> (%)</td></tr><tr><td>Age, year, (mean±SD)</td><td>59.4±13.6</td><td>59.4±13.6</td><td>1.000</td></tr><tr><td... | <table><tr><td rowspan="2">Variable</td><td>Glaucoma group n = 8777</td><td>Control group n = 35,108</td><td rowspan="2">p-value</td></tr><tr><td>n (%)</td><td>n (%)</td></tr><tr><td>Age, year, (mean±SD)</td><td>59.4±13.6</td><td>59.4±13.6</td><td>1.000</td></tr><tr><td>Age, categorical</td><td></td><td></td><td>1.000<... | <table><tr><td rowspan="2">Variable</td><td>Glaucoma group n = 8777</td><td>Control group n = 35,108</td><td rowspan="2">p-value</td></tr><tr><td>n (%)</td><td>n (%)</td></tr><tr><td>No</td><td>7973 (90.8)</td><td>32,830 (90.7)</td><td></td></tr><tr><td>Yes</td><td>804 (9.2)</td><td>3278 (9.3)</td><td></td></tr><tr><td... |
ee7ab18aa0d46dbd66e44866d4ec76e061650bbe6b418b03d3722216acb3e4b3.png | simple | <table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities<... | <table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities<... | <table><tr><td>Municipality</td><td>% Speaking indigenous language</td><td>% Speaking Zapotec monolingual</td><td>% Speaking Zapotec monolingual</td><td>% Of 15 year-old or older who read and write in Spanish</td><td>Average number of years in school</td><td>% Of the population engaged in primary production activities<... |
cadb50118ef6e62d94cf84a57b110c778301194bebfbfdee9c24400682796c15.png | complex | <table><tr><td></td><td>Total cohort</td><td><70 years</td><td>≥70 years</td></tr><tr><td colspan="4">Demographics</td></tr><tr><td> N (%)</td><td>2280</td><td>1497 (65.7)</td><td>783 (34.3)</td></tr><tr><td> Age, mean (SD) [1]</td><td>61.1 (17.0)</td><td>52.2 (13.6)</td><td>78.2 (6.2)</td></tr><tr><td> Gender... | <table><tr><td></td><td>Total cohort</td></tr><tr><td colspan="2">Demographics</td></tr><tr><td>N (%)</td><td>2280</td></tr><tr><td>Age, mean (SD) [1]</td><td>61.1 (17.0)</td></tr><tr><td>Gender (male), n (%) [1]</td><td>1315 (57.7)</td></tr><tr><td>Included at University Medical Centre, n (%)</td><td>1860 (81.6)</td><... | <table><tr><td><70 years</td><td>≥70 years</td></tr><tr><td colspan="2">Demographics</td></tr><tr><td>1497 (65.7)</td><td>783 (34.3)</td></tr><tr><td>52.2 (13.6)</td><td>78.2 (6.2)</td></tr><tr><td>821 (54.8)</td><td>494 (63.1)</td></tr><tr><td>1271 (84.9)</td><td>589 (75.2)</td></tr><tr><td colspan="2">Co-morbidities,... |
71dc2b1b555fd1ad01091f7f12c500533dbf19d3fbc664c92385f53db4be5df4.png | simple | <table><tr><td> </td><td>Before</td><td>After</td></tr><tr><td><i>N</i></td><td>39249</td><td>39249</td></tr><tr><td>Analgesics (<i>N</i>, %)</td><td> </td><td> </td></tr><tr><td> Represcribed pregabalin use</td><td>—</td><td>4009 (10.2)</td></tr><tr><td> 1-2-line drugs</td><td>5416 (13.8)</td><td>3213 (8.2)</td>... | <table><tr><td></td><td>Before</td><td>After</td></tr><tr><td>N</td><td>39249</td><td>39249</td></tr><tr><td>Analgesics (N, %)</td><td></td><td></td></tr><tr><td>Represcribed pregabalin use</td><td>—</td><td>4009 (10.2)</td></tr><tr><td>1-2-line drugs</td><td>5416 (13.8)</td><td>3213 (8.2)</td></tr><tr><td>Continued us... | <table><tr><td>noral opioids</td><td>2.1)</td><td>(8.6)</td></tr><tr><td>Continued use</td><td>—</td><td>702 (1.8)</td></tr><tr><td>New use</td><td>—</td><td>1465 (3.7)</td></tr><tr><td>Changed/added drugs</td><td>—</td><td>527 (1.3)</td></tr><tr><td>Changed/additions of route</td><td>—</td><td>674 (1.7)</td></tr><tr><... |
02efd969449fda1133900ffa9cc1ae791ee732a8c42afcc6610a3c5fef6c0ddd.png | complex | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2"><i>p</i></td></tr><tr><td>Normoxic (<i>n</i> = 196)</td><td>Low O<sub>2</sub> (<i>n</i> = 57)</td></tr><tr><td colspan="4">Pipe type</td></tr><tr><td> No pipe</td><td>14 (7.1)</td><td>4 (7.0)</td><td>0.018∗</... | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2">p</td></tr><tr><td>Normoxic (n = 196)</td><td>Low O2 (n = 57)</td></tr><tr><td colspan="4">Pipe type</td></tr><tr><td>No pipe</td><td>14 (7.1)</td><td>4 (7.0)</td><td>0.018∗</td></tr><tr><td>Iron</td><td>155 (79.1)... | <table><tr><td rowspan="2">Characteristic</td><td colspan="2">No. of wells (column %)</td><td rowspan="2">p</td></tr><tr><td>Normoxic (n = 196)</td><td>Low O2 (n = 57)</td></tr><tr><td>Small tree (<2 m)</td><td>75 (38.3)</td><td>24 (42.1)</td><td>0.712∗</td></tr><tr><td>Hut</td><td>61 (31.1)</td><td>19 (33.3)</td><td>0... |
03ece78a398e326f5ff6c96a87482441506bed89f3a2884c25381c5ba30e3ead.png | complex | <table><tr><td>Characteristic</td><td><i>n</i> = 133</td></tr><tr><td>Age (years)<sup>a</sup></td><td>67.2 ± 9.4</td></tr><tr><td colspan="2">Sex</td></tr><tr><td> Male</td><td>77</td></tr><tr><td> Female</td><td>56</td></tr><tr><td colspan="2">Diagnosis</td></tr><tr><td> Pancreatic carcinoma</td><td>49</td></tr><... | <table><tr><td>Characteristic</td><td>n = 133</td></tr><tr><td>Age (years)a</td><td>67.2 ± 9.4</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Male</td><td>77</td></tr><tr><td>Female</td><td>56</td></tr><tr><td colspan="2">Diagnosis</td></tr><tr><td>Pancreatic carcinoma</td><td>49</td></tr><tr><td>Cholangiocarcinoma<... | <table><tr><td>Characteristic</td><td>n = 133</td></tr><tr><td>Yes</td><td>93</td></tr><tr><td>No</td><td>40</td></tr><tr><td colspan="2">Operation</td></tr><tr><td>PD</td><td>20</td></tr><tr><td>SSPPD</td><td>41</td></tr><tr><td>PPPD</td><td>72</td></tr><tr><td>Operation time (min)a</td><td>454.3 ± 99.8</td></tr><tr><... |
61a9b8109563f5c3a7b5bb74b87c1d956736a6e2b62420b0d7e738dce5df48a2.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Baseline</td><td colspan="2">10% O<sub>2</sub></td><td colspan="2">Recovery</td></tr><tr><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td><td>GFP (<i>n</i> = 4)</td><td>Cre (<i>n</i> = 6)</td></tr><tr><td colspan=... | <table><tr><td rowspan="2"></td><td colspan="2">Baseline</td></tr><tr><td>GFP (n = 4)</td><td>Cre (n = 6)</td></tr><tr><td colspan="3">Heart rate (BPM)</td></tr><tr><td>Pre</td><td>527 ± 13</td><td>504 ± 26</td></tr><tr><td>Post</td><td>495 ± 28</td><td>579 ± 10*</td></tr><tr><td colspan="3">Systolic blood pressure (mm... | <table><tr><td colspan="2">10% O2</td><td colspan="2">Recovery</td></tr><tr><td>GFP (n = 4)</td><td>Cre (n = 6)</td><td>GFP (n = 4)</td><td>Cre (n = 6)</td></tr><tr><td colspan="4">Heart rate (BPM)</td></tr><tr><td>665 ± 11</td><td>656 ± 10</td><td>559 ± 20</td><td>560 ± 26</td></tr><tr><td>665 ± 16</td><td>721 ± 7***<... |
98279206d68c15446545e0d2fbb410b166486853c21f2294ee5aba10f16f67cb.png | simple | <table><tr><td>Markers</td><td>ADHLSC</td><td>BM-MSC [14, 15]</td><td>ASC [15]</td></tr><tr><td>CD73</td><td>98.3% (95.0–99.7)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD90</td><td>91.5% (86.9–95.0)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD105</td><td>96... | <table><tr><td>Markers</td><td>ADHLSC</td><td>BM-MSC [14, 15]</td><td>ASC [15]</td></tr><tr><td>CD73</td><td>98.3% (95.0–99.7)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD90</td><td>91.5% (86.9–95.0)</td><td>≥95% (guideline)</td><td>≥95%</td></tr><tr><td>CD105</td><td>96.7% (93.8–99.6)</td><td>≥95% (guidel... | <table><tr><td>CD36</td><td>3.5% (0.0–12.0)</td><td>0.1% (0.0−0.2)</td><td>11.5% (4.8–13.4)</td></tr><tr><td>CD91</td><td>0.7% (0.0−1.7)</td><td>N.D.</td><td>47.6% (12.7–87.4)</td></tr><tr><td>CD140b</td><td>93.8% (99.4–78.6)</td><td>54.3% (45.9–87.5)</td><td>79.9% (49.2–87.5)</td></tr><tr><td>CD141</td><td>7.2% (4.2–1... |
5145d9384f6aa67cda1b6ad0db21f57d0a63d040c6ae58bea23311dc3fb32d9b.png | simple | <table><tr><td>Measure</td><td>DF</td><td><i>F</i></td><td><i>P</i></td></tr><tr><td>DASS-depression</td><td>1.61</td><td>.24</td><td>.79</td></tr><tr><td>DASS-anxiety</td><td>1.60</td><td>1.72</td><td>.19</td></tr><tr><td>DASS-stress</td><td>1.61</td><td>2.05</td><td>.14</td></tr><tr><td>DASS-total</td><td>1.60</td><t... | <table><tr><td>Measure</td><td>DF</td><td>F</td><td>P</td></tr><tr><td>DASS-depression</td><td>1.61</td><td>.24</td><td>.79</td></tr><tr><td>DASS-anxiety</td><td>1.60</td><td>1.72</td><td>.19</td></tr><tr><td>DASS-stress</td><td>1.61</td><td>2.05</td><td>.14</td></tr></table> | <table><tr><td>DASS-total</td><td>1.60</td><td>1.39</td><td>.26</td></tr><tr><td>FS (Wellbeing)</td><td>1.45</td><td>.57</td><td>.57</td></tr></table> |
df1891314c7a4dd4e3368aa870163c276b00d2751a02c4b1b69a48deb2bac6d9.png | simple | <table><tr><td>Comparison</td><td>P-value</td><td>Comparison</td><td>P-value</td></tr><tr><td>Breast/Colon</td><td>0.0001</td><td>Colon/SCC</td><td>0.135</td></tr><tr><td>Breast/SCC</td><td>0.114</td><td>Colon/KA</td><td>0.027</td></tr><tr><td>Breast/KA</td><td>0.0001</td><td>KA/SCC</td><td>0.0001</td></tr><tr><td>Brea... | <table><tr><td>Comparison</td><td>P-value</td><td>Comparison</td><td>P-value</td></tr><tr><td>Breast/Colon</td><td>0.0001</td><td>Colon/SCC</td><td>0.135</td></tr><tr><td>Breast/SCC</td><td>0.114</td><td>Colon/KA</td><td>0.027</td></tr><tr><td>Brea</td><td>0.0</td><td>KA/</td><td>0.000</td></tr></table> | <table><tr><td>st/KA</td><td>001</td><td>SCC</td><td>1</td></tr><tr><td>Breast (T)/Breast (M)</td><td>0.723</td><td>MSI-High/MSI-Low</td><td>0.443</td></tr></table> |
e98ff0af418732d61fcc861f2306b9feb3c471cb9cab1f015bac02e2e68c2059.png | simple | <table><tr><td></td><td>DL-CNN vs RS1</td><td>AI-CALS vs RS1</td><td>DL-CNN vs RS2</td><td>AI-CALS vs RS2</td></tr><tr><td>Average minimum distance <i>AVDIST</i></td><td></td><td></td><td></td><td></td></tr><tr><td> Pre-treatment</td><td>4.8 ± 1.8mm</td><td>5.3 ± 2.7mm</td><td>4.9 ± 3.4mm</td><td>4.5 ... | <table><tr><td></td><td>DL-CNN vs RS1</td><td>AI-CALS vs RS1</td><td>DL-CNN vs RS2</td><td>AI-CALS vs RS2</td></tr><tr><td>Average minimum distance AVDIST</td><td></td><td></td><td></td><td></td></tr><tr><td>Pre-treat</td><td>4.8 </td><td>5.3 ± 2</td><td>4.9 ± 3.</td><td>4.5 ± 1.</td></tr></table> | <table><tr><td>ment</td><td>± 1.8mm</td><td>.7mm</td><td>4mm</td><td>9mm</td></tr><tr><td>Post-treatment</td><td>4.3 ± 1.7mm</td><td>4.4 ± 1.8mm</td><td>4.7 ± 3.1mm</td><td>4.9 ± 3.7mm</td></tr><tr><td>Both</td><td>4.6 ± 1.8mm</td><td>4.8 ± 2.3mm</td><td>4.8 ± 3.2mm</td><td>4.7 ± 2.9mm</td></tr><tr><td>Jaccard index JA... |
096d7922908e0c35c1bc02398a4b3f083e2fe475b7d977c0ec3d93ca29e731e7.png | complex | <table><tr><td>Targets</td><td colspan="3">MLC leaf width</td></tr><tr><td></td><td>10 mm</td><td>4 mm</td><td><i>p </i>value</td></tr><tr><td>Pgtv</td><td></td><td></td><td></td></tr><tr><td> Dmax</td><td>7056.1 ± 127.2</td><td>6996.3 ± 88.9</td><td>0.24</td></tr><tr><td> Dmin</td><td>6035.5 ± 113.7</td... | <table><tr><td>Targets</td><td colspan="3">MLC leaf width</td></tr><tr><td></td><td>10 mm</td><td>4 mm</td><td>p value</td></tr><tr><td>Pgtv</td><td></td><td></td><td></td></tr><tr><td>Dmax</td><td>7056.1 ± 127.2</td><td>6996.3 ± 88.9</td><td>0.24</td></tr><tr><td>Dmin</td><td>6035.5 ± 113.7</td><td>6132.2 ± 107.4</td>... | <table><tr><td>Dmean</td><td>5478.5 ± 78.4</td><td>5489.2 ± 64.3</td><td>0.74</td></tr></table> |
b311723db2e831a2b1e5d1f8a6b3f1dd2bc06dc5819f293ce53998c9b9038f4b.png | simple | <table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Bolungarvik</td><td>11</td><td>2.08</td><td>0.79</td><td>0.24</td><td>0.21</td><td>0.29</td><td>0.25</td></tr><tr><td>Grafarvogur, Reykjavik</td><td>12</td><td>2.33</td><td>0.65</td><td>0.43</td><td>0.26<... | <table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Bolungarvik</td><td>11</td><td>2.08</td><td>0.79</td><td>0.24</td><td>0.21</td><td>0.29</td><td>0.25</td></tr><tr><td>Grafarvogur, Reykjavik</td><td>12</td><td>2.33</td><td>0.65</td><td>0.43</td><td>0.26<... | <table><tr><td>Location</td><td>N</td><td>A</td><td>SD</td><td>Ho</td><td>SD</td><td>He</td><td>SD</td></tr><tr><td>Sveinbjarnargerdi</td><td>8</td><td>3.50</td><td>1.17</td><td>0.36</td><td>0.18</td><td>0.47</td><td>0.15</td></tr><tr><td>Total/mean</td><td>81</td><td>2.40</td><td>0.83</td><td>0.28</td><td>0.23</td><td... |
b99faf885af8fe999155fbceb4bc65ecf39173d1834e8e6c43708a10e95ce429.png | complex | <table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted OR<sup>a</sup> (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Total<sup>b</sup></td><td>3750</td><td></td><td>326</td><td><... | <table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted ORa (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Totalb</td><td>3750</td><td></td><td>326</td><td></td><td></td><td></td>... | <table><tr><td></td><td colspan="2">Females</td><td colspan="2">Males</td><td>Unadjusted OR (95 % CI)</td><td>Adjusted ORa (95 % CI)</td></tr><tr><td></td><td>Number</td><td>Percent</td><td>Number</td><td>Percent</td><td></td><td></td></tr><tr><td>Positive</td><td>2211</td><td>77.3</td><td>236</td><td>96.7</td><td>8.67... |
5a6b6d6848733a37ef5cacc39e4bd5344cdbbfd0977aabb9b6e87b0dab0a175d.png | simple | <table><tr><td></td><td>Daily Cannabis Users</td><td>Cannabis Non-Users</td></tr><tr><td>Sample Size (N)</td><td>243</td><td>244</td></tr><tr><td>Gender</td><td>81% male; 19% female</td><td>51% male; 49% female</td></tr><tr><td>Average Age*</td><td><i>M </i>= 37.8, <i>SD </i>= 13.3</td><td>M = 28.2, <i>SD </i>= 11.0</t... | <table><tr><td></td></tr><tr><td>Sample Size (N)</td></tr><tr><td>Gender</td></tr><tr><td>Average Age*</td></tr><tr><td>Maximum Income Bracket**</td></tr></table> | <table><tr><td>Daily Cannabis Users</td><td>Cannabis Non-Users</td></tr><tr><td>243</td><td>244</td></tr><tr><td>81% male; 19% female</td><td>51% male; 49% female</td></tr><tr><td>M = 37.8, SD = 13.3</td><td>M = 28.2, SD = 11.0</td></tr><tr><td>M = $44,431, SD = $23,027</td><td>M = $39,640, SD = $24,159</td></tr></tabl... |
4057718aeafec0824e6a03fa0033e9aac608b4e4ddc5ce6ccbca7f24157bb182.png | simple | <table><tr><td>Causative factors</td><td>Numbers</td></tr><tr><td>Antenatal</td><td>38 (11.7 %)</td></tr><tr><td>Intrapartum</td><td>220 (67.9 %)</td></tr><tr><td> Placental abruption</td><td>87</td></tr><tr><td> Cord prolapse</td><td>16</td></tr><tr><td> Uterine rupture</td><td>15</td></tr><tr><td> Maternal hypoxic ev... | <table><tr><td>Causative factors</td><td>Numbers</td></tr><tr><td>Antenatal</td><td>38 (11.7 %)</td></tr><tr><td>Intrapartum</td><td>220 (67.9 %)</td></tr><tr><td>Placental abruption</td><td>87</td></tr><tr><td>Cord prolapse</td><td>16</td></tr><tr><td>Uterine rupture</td><td>15</td></tr><tr><td>Maternal hypoxic event<... | <table><tr><td>Unknown causes</td><td>4</td></tr><tr><td>Total</td><td>324</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.